Memorial Sloan Kettering Cancer Center Weill Cornell Medical

Memorial Sloan Kettering Cancer Center

Weill Cornell Medical College

CURRICULUM VITAE

Name: Eileen M. O’Reilly, M.B., B.Ch., B.A.O., B.A. (M.D.)

Date of update:

October, 2015

A. GENERAL INFORMATION

1. Name

2. Office address:

Office telephone:

Office fax:

3. Home address:

Eileen M. O’Reilly


300 East 66 th street, office 1021

New York, NY 10065

646 888-4182

646 888-4254

418 East 59 th Street

B.

Home telephone:

4. Cell phone:

5. Email:

6. Citizenship:

If not USA, do you have:

An immigrant visa or

A non-immigrant visa?

EDUCATIONAL BACKGROUND

1. Degree

Degree Institution name and location

Apt. 33A

New York, NY 10022

(212) 755-6762

(646) 552-8990/ (203) 675-9360

oreillye@mskcc.org

Irish, US

Dates attended Year Awarded

B.A.

B.Ch.

B.A.O.

M.B.

Trinity College (Dublin University)


St. James’s Hospital, Dublin





1984- 1990

1984- 1990

1984- 1990

1984- 1990

1990

1990

1990

1990

1

C. PROFESSIONAL POSITIONS AND EMPLOYMENT

1. Post-doctoral training including residency/fellowship

Title

Institution name and location

Intern

Resident (SHO),

Internal Medicine


Wexford Regional Hospital, Wexford


Waterford Regional Hospital, Waterford

St. Vincent’s Hospital, Dublin Registrar (Fellow),

Internal Medicine &

Medical Oncology

Research Fellow

Memorial Sloan Kettering Cancer Center,

NY, NY

Fellowship, Medical

Oncology

Fellowship, Medicine

NY, NY

2. Academic positions (teaching and research)

Title


NY, NY

Cornell University Medical Center

Clinical Assistant

Institution name and location


NY, NY

Instructor in Medicine

Assistant Member


NY, NY


Assistant Professor of

Medicine

Consultant Medical

Oncologist

Assistant Member

NY, NY


NY, NY

Meath & Adelaide, Inc. the National

Children’s Hospital, Tallaght, Dublin 24

Ireland


NY, NY

Dates held

1990- 1991

1991- 1993

1993- 1995

1995- 1997

1995- 1997

1995- 1997

Dates held

07/97- 09/01

07/97- 10/01

09/01- 05/02

11/01- 05/02

07/02- 12/02

01/03- 02/07

2

Assistant Professor of Weill Cornell Medical College

Medicine

Associate Member,

Memorial Hospital

Member,

Memorial Hospital

Associate Professor of

Medicine

Associate Director,

Clinical Research

NY, NY


NY, NY


NY, NY


NY, NY

Rubenstein Pancreatic Cancer Research,


3. Hospital positions (e.g., attending physician)

Title

Institution name, city and state

Clinical Assistant

Physician

Gastrointestinal Oncology Service

Memorial Hospital for Cancer and Allied

Diseases, NY, NY

Assistant Attending

Physician (Level 1)

Assistant Attending

Physician

Associate Attending



Diseases, NY, NY



Diseases, NY, NY


Physician

Attending Physician


Diseases, NY, NY



Diseases, NY, NY

4. Other Employment

Title

Consultant Medical

Oncologist

Institution name, city and state

Meath & Adelaide, Inc. the National

Children’s Hospital, Tallaght, Dublin 24

Ireland

3

07/04- 02/08

03/07- 03/15

04/15- Present

03/08- Present

03/14- Present

Dates

07/97- 09/01

09/01- 05/02

01/03- 02/07

03/07- 03/15

04/15- Present

Dates

5/02- 12/31/02

D. LICENSURE, BOARD CERTIFICATION, MALPRACTICE

1. Licensure

Type

New York State (207549-1)

DEA number (B05459006)

Infection Control

Irish Medical Council (14776)

Date of Issue

7/24/1997

Last Issued:

11/19/2014

11/2014

07/2014

Date of expiration

01/31/2017

12/31/2017

11/2018

Present

2. Board Certification

Name of specialty

Internal Medicine

Board Certificate #

N/A

Date of Certification

11/131992 (RCPI) Ireland

3. Malpractice insurance

Do you have Malpractice insurance?

Name of Provider:

Premiums paid by: Institution (

Yes

Memorial Sloan Kettering Cancer Center)

E. PROFESSIONAL MEMBERSHIPS (medical and scientific societies )

Member/officer Name of Organization

Member

Member

MSK Insurance US, Inc.

Royal College of Physicians of Ireland (RCPI)

European Society of Medical Oncology (ESMO)

Dates held

1992- Present

1993- Present

Member

Member

Member

Member

Member

Member

Member

Member

European School of Oncology (ESO)

American Society of Clinical Oncology (ASCO)

1993- Present

1995- Present

Irish Society of Medical Oncology (ISMO)

Alliance (former CALGB)

American College of Surgeons (ACOSOG)

American College of Radiology Imaging

2000- Present

2000- Present

2003- 2012

2006- 2012

Network (ACRIN)

American Association of Cancer Research (AACR) 2014- Present

National Comprehensive Cancer Network (NCCN) 2013- Present

4

Chair

Pancreas Cancer Task Force

F. HONORS AND AWARDS

Name of award

John Mallet Purser Memorial Medal

Upjohn Prize

Mari-Curie Memorial Prize

Walter G. Smith Bequest

1 st place overall Graduation Medical School (TCD)

First Class Honors/ Obstetrics & Gynecology

Second Class Honors/ Medicine, Surgery, Psychiatry

Fitzpatrick Scholarship

Sir James Craig Memorial Prize

G.B. Hutchinson Bequest

Reuben Harvey Prize (R.C.P.I.)

Norman Connolly Memorial Medal in Mental Diseases

Coombe Hospital Silver Medal (Obstetrics, Gynecology)

Professor’s Prizes (Medicine, Obstetrics, Gynecology, Surgery)

St. James’s Hospital Gold Medal

European School of Oncology Breast Scholarship

Faculty Teaching Award (Solid Tumor Division), MSKCC




Ireland/Northern Ireland/National Cancer Institute Clinical Trials

Initiative Award 2002, €240,000 (over 2 years)

New York Magazine ‘Best Doctors’ (Oncology)











Claude Smith Lectureship Pancreas Cancer, Johns’ Hopkins CC

Saint Frances de Sales Award of Outstanding Service

Nobility in Science Award (National Pancreas Foundation)

5

2013- Present

Date awarded

2005

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2011

2014

2014

1987

1987

1988

1998

1990

1990

1990

1990

1990

1990

1990

1990

1990

1990

1990- 1991

1994

1997- 1998

1998- 1999

2000- 2001

2001- 2002

2002- 2004

Paul Sherlock House Staff Teaching Award 2014- 2015

H.

G. INSTITUTIONAL/HOSPITAL AFFILIATION

Primary Hospital Affiliation: Memorial Hospital for Cancer and Allied

Diseases

Other Hospital Affiliations:

Other Institutional Affiliations:

None


EMPLOYMENT STATUS

Name of Employer(s): Memorial Sloan-Kettering Cancer Center

Employment Status:

• Full-time

6

I. CURRENT AND PAST INSTITUTIONAL RESPONSIBILITIES AND EFFORT

1. Teaching/ Mentoring (list courses and your role)

Fellow Presentation: Hereditary Breast Cancer

Fellow Presentation: Early stage ovarian Cancer: Adjuvant Therapy

Resident House Staff Lectures and Morning Report

Resident House Staff: Neuroendocrine cancers and paraneoplastic syndromes

Resident House Staff: Upper Gastrointestinal Malignancies

Morning Report: Gastric & Esophageal Cancers: Multimodality Therapy

Resident House Staff Lecture: Pancreas Cancer



House staff Lecture: Pancreas Adenocarcinoma/Neuroendocrine Cancers

MSKCC House staff Lecture: Pancreas cancer

Morning Report: Neuroendocrine cancers

House Staff: Pancreas Adenocarcinoma and Neuroendocrine Tumors

Morning Report: Biliary Cancers.

House Staff Morning Report: Pancreas Neuroendocrine cancers

House Staff: Pancreas Adenocarcinoma and Neuroendocrine Tumors

House Staff: Morning Report

House Staff lecture: Pancreas Adenocarcinoma – New Developments

House Staff Morning Report: Biliary Cancers

House Staff lecture: Genetics and treatment for Pancreas/Biliary Cancers

House Staff lecture: Pancreas Adenocarcinoma

House Staff Morning Report: Pancreas cancer, liver failure, adjuvant therapy

House Staff lecture: Pancreas and Neuroendocrine cancers

House Staff: Biliary cancers

House Staff lecture: Pancreas and Neuroendocrine cancers

House Staff lecture: Pancreas cancer

House Staff lecture: Pancreas cancer

Morning Report: Pancreas malignancies

Morning Report: Pancreas/Biliary cancer

Morning Report: Pancreas/neuroendocrine

2013

2014

2014

2014

2014

2014

2014

2015

2011

2011

2011

2012

2012

2012

2012

2012

2005

2006

2007

2007

2009

2010

2011

2011

Dates

1995

1996

1997

1997

1998

House Staff lecture: Pancreas adenocarcinoma

Morning Report: Pancreas neuroendocrine

Morning Report: Pancreas adenocarcinoma

Medical Oncology Fellowship Core Lectures (MSKCC)

Pancreas Cancer and Upper GI malignancies

Hepatopancreaticobiliary malignancies

Pancreatic Cancer

Pancreas and Neuroendocrine cancers

Pancreatic Cancer: Current update & Novel therapeutics

Pancreatic Cancer: Treatment Advances?

Pancreatic Cancer: Progress – Fact or Fiction?

Pancreas Adenocarcinoma

Pancreas Cancer: Developments and new Directions

Pancreas Cancer: Current Standards and Future Directions


Pancreas Malignancies

2015

2015

2015

1998

1999

2000

2002

2004

2006

2007

2008

2009

2010

2011

2013

7



Surgical Oncology Fellowship Core Lectures (MSKCC)

New Drugs in Gastrointestinal Malignancies

Pancreaticobiliary Malignancies: Medical oncology issues

Adjuvant Therapy for Pancreatic Cancer (Chairman’s Conference)

Pancreas Adenocarcinoma: Adjuvant Therapy

Pancreatic Cancer: Current update & Novel therapeutics

Pancreatic Cancer

Pancreatic Cancer: Adjuvant & Neoadjuvant therapy

Pancreatic Cancer: Controversies in Adjuvant therapy

Adjuvant & Neoadjuvant Therapy PC

Adjuvant & Neoadjuvant therapy: Treatment Advances

Adjuvant & Neoadjuvant therapy: Treatment Advances

Adjuvant, Neoadjuvant, Borderline Resectable PC

Adjuvant, Borderline Resectable and new Metastatic Developments

Pancreatic Cancer: Spectrum of Disease (Gastroenterology)

Undergraduate Teaching International

Undergraduate & Postgraduate medical oncology training (Ireland)

Medical Oncology Teaching Module (2



Medical Oncology Teaching Module (2 nd nd nd nd

Year students). Balamand University




Medical Oncology Teaching Module (2 nd nd



Medical Oncology Teaching Module (2 nd


Medical Oncology Teaching Module (2 nd



Fellows Teaching Videolink/Other

Gastrointestinal Fellowship MSKCC: International Fellow



Acinar and Neuroendocrine Pancreatic Cancer

Acinar Pancreatic Cancer

Pancreatic Cancer

Acinar and Neuroendocrine Pancreatic Cancer

Rare GI Oncology Cases

Familial Pancreatic Cancer

Unknown Primary Cancer

Pancreas adenocarcinoma

Neuroendocrine cancer

Neoadjuvant therapy for pancreas adenocarcinoma

Neuroendocrine cancer

Unknown primary cancer

Fellowship Teaching conferences

GI Journal Club – weekly teaching/Case presentation

Pancreas adenocarcinoma

Nursing Education lecture: Pancreas Malignancies

8

2014

2015

2002

2003

2004

2006

2007

2008

2009

2010

2011

2003- 2004

2004- 2005

2006- 2008

2005

2006

2008

2008

2009

2011

2013

2014

2015

1998

2000

2000

2003

2004

2009

2009

2009

2010

2010

2010

2011

2011

2012

2013

2013

2013

2003- 2010

2008- 2011

2014

2015

Other Lectures/Teaching/Courses

Colon Cancer: What every man and woman should know. Public Education

Conference Series, MSKCC

Pancreatic Cancer: Update & New developments (NM Seminar, MSKCC)

MSKCC Society Board Lecture: Pancreas Cancer

NCI Cancer Information Service: Pancreas Cancer (MSKCC)

MSKCC Alumni meeting: Pancreatic Cancer Therapeutic Challenges

NCI Cancer Information Service: Pancreas Cancer (MSKCC)

MSKCC Pharmacy: Pancreas Adenocarcinoma Therapeutic Challenges

Cancer Smart MSKCC Public Lecture: Pancreas Cancer

Pancreatic Cancer Action Network Public Symposium (Washington)

Pancreatic Cancer Action Network Public Symposium (New York)

Oncology Nursing Society: Pancreas Cancer

Public Education Lecture Pancreas Cancer: Hackensack

Pancreatic Cancer Action Network Public Symposium (New York)

MSKCC Board Review: Pancreas and Neuroendocrine Malignancies



Co-Director: Pancreas Cancer Symposium MSKCC

Co-Chair: Inaugural MSKCC and the American University of Beirut (MSKCC-AUB)

Joint Course in Oncologic Sciences, Beirut, Lebanon

Co-Chair: National Pancreas Foundation Fellows Symposium

Co-Chair: National Pancreas Foundation Fellows Symposium

Co-Chair: Hamad Medical Corporation Hosted Second MSKCC and the American

University of Beirut (MSKCC-AUB) Joint Course in Oncologic Sciences, held jointly

with Hamad Medical Corporation and Weill-Cornell Medical College-Qatar

(WMCMC-Q), Doha, Qatar.

2. Mentoring (Fellowship/Junior Faculty/House Staff)

Jason Konner, M.D. (Sub-specialty GI Fellowship, Faculty, MSKCC)

Gregory Leonard, M.D. (Sub-specialty GI Fellowship, Consultant, Ireland)

Austin Duffy, M.D. (Sub-specialty GI Fellowship;; Investigator NCI).

Andrew Epstein, M.D. (Medical Oncology Fellow, Palliative Care Fellow, Sinai)

Andrew Epstein M.D. (Junior Faculty, MSKCC)

Maeve Lowery, M.D. (Sub-specialty GI Fellowship)

Maeve Lowery, M.D. (Junior Faculty, MSKCC)

Kenneth Yu, M.D. (Junior Faculty, MSKCC)

Anna Perelshteyn, M.D. (House Staff, Columbia Presbyterian, MSKCC)

Pavan Mankal, M.D. (House Staff, St. Luke’s Roosevelt, MSKCC)

Paula Gorniaczyk (Bronx High School Student)

Ibrahim Sahin, M.D. (House Staff, St. Luke’s Roosevelt, MSKCC)

Wungki Park, M.D. (House Staff, MSKCC)

Daneng Li, M.D. (Fellow, MSKCC)

Andrew Yang, M.D. (House Staff, St Luke’s Roosevelt/Fellow MSKCC)

Govindarajan Srimathaveeravilli, PhD (Junior Faculty, MSKCC)

1999

2011

2014

2014

2014

2013

2014

2015

1999

2004

2004

2006

2007

2008

2008

2010

October 2010

June 2013

April 2014

April 2015

October 2014

2003- 2004

2003- 2005

2006- 2008

2009- 2011

2012-

2009- 2012

2012-

2010-

2012- 2014

2013- 2014

2013- 2015

2013-

2013- 2015

2013- 2015

2014- 2015

2014- 2014

9

Angel Mier Hicks, M.D. (House Staff, St. Luke’s Roosevelt, MSKCC)

Yasmina Tbeur, M.D. (House Staff, St. Luke’s Roosevelt, MSKCC)

Andrea Cheema, M.D. (House Staff, St. Luke’s Roosevelt, MSKCC)

3. Clinical Care

Two full clinic day per week

In patient rounds and consultations

Medical care of outpatients

Dates

2015-

2014-

2015-

Mondays, Tuesdays, weekly

4 weeks approx per year

Daily

4. Administrative Responsibilities (including committees)

Institutional Review & Privacy Board (IRB), Member

Institutional Review & Privacy Board (IRB), Associate Chair

Chemotherapy Redesign Steering Committee, Member

Electronic Chemotherapy Order Committee, Member

President-Elect Medical Staff, MSKCC

President Medical Staff, MSKCC

Clinical Council Committee, Member

Research Council, Member

Medical Board, Member

Dates

2003- 2013

2013-

2004- 2008

2005- 2012

2007- 2009

2009- 2011

2008- 2014

2008-

2007- 2013

Gastrointestinal Oncology Patient Flow Project (Co-Chair)

2010- 2012

Search Committees (multiple: Hepatopancreaticobiliary Service

Chief, Physician-in Chief, Gastrointestinal Oncology Chief)

2009, 2011, 2012

David M. Rubenstein Pancreatic Center Search (Co-Chair Search) 2013

2014- David M. Rubenstein Pancreatic Center:

Associate Director for Clinical Research

Chair, Continuing Medical Education (CME)

Quality Informatics Committee, Member

2015-

2015-

5. Research

I am an academic clinical investigator focused primarily on pancreas and biliary cancers. Research initiatives include development of molecularly targeted therapy for pancreas cancer with a particular focus on BRCA-related pancreas cancer, neoadjuvant strategies and developing novel therapies for advanced pancreas cancer.

Institutionally, I have collaborative research efforts in pancreas cancer with surgery, gastroenterology, radiation oncology, genetics, pathology, epidemiology, psychiatry behavioral and basic sciences.

10

Percent effort

Teaching

Clinical Care

Administration

Research

Total

%

10

25

20

25

100%

Does activity

Involves WCMC

Does activity involves MSKCC

Students or researchers

Trainees or

Researchers

Yes

Yes

Yes

Yes

Dates

1997- Present

1997- Present

2003- Present

1997- Present

Yes

Yes

Yes

Yes

J. RESEARCH SUPPORT (past and present)

1. Current Support

Date

2004-

2010-

2009 -2015

2007- 2015

Title of Grant/Source, Name of Principal Investigator

Pancreatic Cancer Research Fund. PI.

Andrea J. Will Foundation Pancreas Fund. PI.

A phase I trial of gemcitabine and KSR inhibitor in advanced pancreas adenocarcinoma. PI.

A Phase II study of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas cancer. PI and Study Chair.

IRB #07-113.

Amount

(% Effort)

$1,101,019

(10%)

$92,570

(5%)

Experimental

Therapeutics

Grant (5%)

$136,000

Industrial Contract

(10%)

$128,510

2009- 2015

2009- 2016

2010-

2011-

A Phase I-II study of gemcitabine and a PARP inhibitor, AZD

2281 (KU-0059436). PI. IRB #09-073.

A phase II study of AGS-1C4D4 in combination with gemcitabine in advanced pancreas cancer. PI. IRB #09-086.

A Phase IIR and a Phase II Trial evaluating both Erlotinib (Ph

IIR) and Chemoradiation (Phase III) as Adjuvant Treatment for

Patients with Resected Head of Pancreas Adenocarcinoma.

MSKCC Co-PI. IRB #10-083.

Feasibility of Obtaining and Characterizing Circulating Tumor

Cells in Patients with Pancreatic Adenocarcinoma. Co-PI. IRB

#11-141.

Industrial Contract

(10%)

$279,366

Industrial Contract

(10%)

$240,786

NCI/ Alliance

(10%)

R/D Powell CC

46850 Fund

#256560

Peer Reviewed

(Lee) CC62060l

Fund #14690

NIH K08

ES019615 (0%)

$27,750

11

2012- 2016

2012- 2017

2012- 2017

2012- 2017

2012-

2012-

2012- 2016

2012-

2013-

2013-

2014-

2014-

2014- 2018

2014-

A Phase IB, Open-label, Multi-center, Dose Escalation, Safety and Tolerability Study of LDE225 in Combination with

Gemcitabine in Patients with Locally Advanced or Metastatic

Pancreatic Adenocarcinoma. MSKCC Co-PI. IRB #12-036.

A Randomized Phase II Trial of Gemcitabine, Cisplatin +/-

Veliparib in BRCA/ PALB2 Mutated Pancreas Adenocarcinoma

(Part I). NCI #8993. PI and Study Chair. IRB #12-045

A Phase II Single-Arm Study of Single-Agent Veliparib in

Previously Treated Pancreas Adenocarcinoma (Part II). NCI

#8993. PI and Study Chair. IRB #12-045.

Correlative Studies in BRCA1, BRCA2 and PALB2 Mutated

Advanced Pancreas Adenocarcinoma Receiving Systemic

Therapy Including a PARP Inhibitor. PI and Study Chair. IRB

#12-045.

A Phase I-II, Two-Part, Multicenter Study to Evaluate the

Safety and Efficacy of M402 in Combination with Nab-

Paclitaxel and Gemcitabine in Patients with Metastatic

Pancreatic Cancer. PI and Study Chair. IRB #12-078.

A Phase IB-II Study of OMP-59R5 in Combination with Nab-

Paclitaxel and Gemcitabine in Subjects with Previously

Untreated Stage IV Pancreatic Cancer. PI and Study Chair.

IRB #12-234.

A Phase IB Study of Fractionated 90Y-hPAM4 with or without

Gemcitabine in Patients with Metastatic Pancreatic Cancer who

Received at Least Two Prior Treatments. Co-PI MSKCC. IRB

#12-208.

Myriad Genetics. PI.

Person-Centered Oncology Care and Choices (P-COCC):

Piloting and Initial Randomized Testing of a Combined Values

Narrative Interview and Video Education Advance Care

Planning Program in Gastrointestinal Oncology Patients. Co-PI.

IRB #13-120.

Industrial Contract

(5%)

$47,551

CTEP/NCI

(10%)

U01 $504,000

CTEP/NCI

(10%)

U01 $504,000

Lustgarten

Foundation (10%)

$609,485

Industrial Contract

(10%)

$263,983

Industrial Contract

(7.5%)

$102,089

Industrial Contract

(5%)

$150,921

$20,850 (10%)

Peer-Reviewed

Grant (0%)

$154,000

A Registry for BRCA Mutation Carriers with Pancreatic Ductal

Adenocarcinoma. Co-PI MSKCC. IRB #13-217.

A Phase 0, Two-Stage Study of Single Dose PEGPH20 and

Cetuximab in Patients with Pancreatic Adenocarcinoma Prior to

Surgical Resection. Co-PI MSKCC. IRB #14-039.

Coping with Cancer II. Co-PI MSKCC. IRB #14-048.

Lustgarten

Grant (0%)

$220,853

Lustgarten Grant

(0%)

$227,068

Peer-Reviewed

Grant (0%)

R01-CA106370

$95,173

A Phase III, Multicenter, Open-Label, Randomized Study of nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone As

Adjuvant Therapy in Subjects with Surgically Resected

Pancreatic Adenocarcinoma. MSKCC PI and Steering

Committee Member. IRB #14-120.

A Phase IB Trial of ADI PEG 20 Plus Nab-Paclitaxel and

Gemcitabine in Subjects with Advanced Pancreas Cancer.

Co-PI MSKCC. IRB #14-133.

Industrial Contract

(10%)

$977,998

Industrial Contract

(5%)

Pending

12

2014- 2017

2015-

2015-

Pending

2014-

2014-

A Randomized, Double-Blind, Phase 3 Study of the JAK1/2

Inhibitor, Ruxolitinib or Placebo in Combination with

Capecitabine in Subjects With Advanced or Metastatic

Adenocarcinoma of the Pancreas Who Have Failed or Are

Intolerant to First-Line Chemotherapy (JANUS 2 Study). PI and Study Chair. IRB #14-190.

A Phase I-II Study of the Safety and Efficacy of Ulocuplumab

Combined with Nivolumab in Subjects with Advanced or

Metastatic Solid Tumor Malignancies

PI. IRB #15-179

A Phase II Open-Label, Multi-Center Study of MEDI4736

Evaluated as Single Agent or in Combination with

Tremelimumab in Patients with Metastatic Pancreatic Ductal

Adenocarcinoma

PI and Global PI. IRB #15-YYY

K25 CA178216 (PI: Houghton)

Modular Strategies for Developing ImmunoPET Imaging

Agents for Pancreatic Cancer.

GC221859 (PI: Li)

Conquer Cancer Foundation of the American Society of Clinical

Oncology.

Pharmacogenomic Profiling of Circulating Tumor Cells in

Patients with Metastatic Pancreas Adenocarcinoma Treated with Gemcitabine and Nab-Paclitaxel.

2014-

2014-

2. Past Support

GC222128 (PI: Lowery)

Clinical and Translational Study of PARP inhibition in BRCA 1-

2 and PALB2 mutation associated pancreas cancer.

GC223146 (PI: Leach)

Center for Molecular Oncology

Analysis of pre and post treatment ctDNA in pancreatic cancer patients

Date Title of Grant/Source, Name of Principal Investigator(PI)

1996

1997

1997

1997

1997

A phase II trial of 96 hour paclitaxel in patients with esophageal carcinoma. Fellow. IRB #96-63.

A phase II trial of irinotecan in patients with advanced malignant mesothelioma. Fellow. IRB #97-44.

A phase II trial of cisplatin and irinotecan in patients with advanced esophageal and gastric cancers. Fellow. IRB #97-

60.

A phase II trial of irinotecan in advanced biliary tract tumors

(hepatocellular cancer, gallbladder and cholangiocarcinomas).

PI and Study Chair. IRB #97-80.

A pilot phase I/II trial of adjuvant K-ras vaccination in patients with resected pancreatic adenocarcinoma. PI. IRB #97-139.

Industrial Contract

(10%)

$1,630,592

Industrial Contract

(10%)

$ Pending

Industrial Contract

(10%)

$ Pending

04/01/14-

03/31/19 (0%)

$96,843

07/01/14-

06/30/15 (0%)

$47,500

07/01/13-

06/30/2016 (0%)

$62,466

07/01/14-

06/30/015 (0.12)

$100,000

Amount

(% Effort)

N/A

N/A

N/A

Industrial

Contract (5%)

$106,459

Exxon Grant

(5%)

13

1998- 2001

1999- 2003

1999- 2003

1999- 2002

1999- 2002

1999- 2002

2000- 2002

2001- 2002

2002- 2006

1997- 2000

1998- 2000

2002- 2004

2003- 2008

2003- 2006

2004- 2008

2005- 2008

A phase I trial of gemcitabine and irinotecan in patients with advanced solid tumor malignancies. PI. IRB #97-92.

A phase II trial of SCH 66356, a farnesyl transferase protein inhibitor, versus a reference agent, gemcitabine, in patients with advanced pancreatic cancer. PI. IRB #98-115.

A phase I study of combined gemcitabine and radiation in patients with locally advanced unresectable pancreatic adenocarcinoma. PI. IRB #98-019.

A phase II trial of DX-8951f, a synthetic camptothecin, in patients with advanced pancreatic cancer. PI and Study Chair.

IRB #99-14.

A phase II trial of SCH 66336 and 5-Fluorouracil in advanced cancer. Co-PI MSKCC. IRB #99-20.

A phase II trial of DX-8951f in patients with hepatocellular carcinoma and cholangiocarcinomas. PI and Study Chair. IRB

#99-58.

A phase II trial of DX-8951f in patients with cholangiocarcinoma and gallbladder cancers. PI and Study Chair. IRB #99-110.

A phase II trial of DX-8951f, a synthetic camptothecin, in patients with advanced pancreatic cancer. PI. IRB #99-014

A phase I trial of combination DX-8951f and gemcitabine in advanced solid tumors. PI. IRB #00-051.

NIH R-21 CA 96535 (two years). PI

A randomized, open-label, multi-center phase III study comparing the a combination of intravenous DX-8951f plus gemcitabine to gemcitabine alone in patients with locally advanced or metastatic cancer of the exocrine pancreas. PI and Study Chair. IRB #02-011.

Ireland/Northern Ireland/National Cancer Institute Clinical Trials

Initiative Award 2002. PI. (€240,000)

A phase II study of Interferon-based adjuvant chemoradiation in patients with resected pancreatic adenocarcinoma (Z05031).

MSKCC PI. IRB #03-115.

A phase I study of twice-weekly gemcitabine, daily erlotinib and radiation in locally advanced, unresectable pancreas cancer.

PI and Study Chair. NCI #5441. IRB #03-031.

A randomized phase III trial of gemcitabine plus bevacizumab versus gemcitabine plus placebo in patients with advanced pancreatic cancer (CALGB 80303). PI. IRB #04-111.

An open-label, non-randomized phase II study of flavopiridol in combination with docetaxel in refractory metastatic pancreas cancer. NCI #6366. PI. IRB #05-136.

Industrial

Contract (10%)

$90,000

Industrial

Contract

(5%)

$55,418

Industrial

Contract (10%)

$54,551

Industrial

Contract (10%)

$248,280

Industrial

Contract (5%)

$190,000

Industrial

Contract (10%)

$261,880

Industrial

Contract (10%)

$246,050

Industrial

Contract

$248,280

Industrial

Contract (10%)

$265,400

$150,000 (5%)

Industrial

Contract (10%)

$382,515

Funding in

Ireland (50%)

$322,260

ACOSOG

Institutional

Grant (10%)

Phase I NCI

Contract (10%)

CALGB

Institutional

Contract (10%)

$228,589

Phase II NCI

Contract (10%)

$371,349

14

2005- 2008

2007- 2011

2010- 2014

A phase III randomized open-label study comparing gemcitabine plus IMC-225 (Cetuximab) versus gemcitabine as first-line therapy for patients with advanced pancreatic cancer.

SWOG. CALGB Co-Chair.

A phase II study of sunitinib malate in patients with previously treated pancreatic adenocarcinoma with measurable metastatic disease following progression on front-line gemcitabine-based therapy (CALGB 80603). PI and CALGB Study Chair. IRB

#07-037.

Phase II and Multi-institutional Study to Evaluate Gemcitabine and Fractionated Stereotactic Radiotherapy for Unresectable

Pancreas Adenocarcinoma. MSKCC Co-PI. IRB #11-178.

2010- 2014

Cardiopulmonary resuscitation (CPR) Video to Enhance

Advance Care Planning in Advanced Pancreas and

Hepatobiliary Cancer Patients. PI. IRB #10-043.

K.

EXTRAMURAL PROFESSIONAL RESPONSIBILITIES

National Activities

N/A (1%)

CALGB

Institutional

Contract (10%)

$228,589

Stanford –

John’s Hopkins

Grant (0%)

YIA Grant (0%)

$47,500

1999

2000

2000- 2011

NIH Pancreatic Think Tank Committee. Salt Lake City, Utah

NIH Pancreatic Progress Review Group. Virginia

AJCC Digestive Task Force Staging Committee

(National reference AJCC adjudicator re staging)

Cancer Initiative: Visiting Professorship



Daiichi Phase III Pancreatic Trials (US, Europe)

Chairperson, Steering Committee

American Society of Clinical Oncology (ASCO)

ASCO: Gastrointestinal, Non-Colorectal Program Committee

ASCO: Gastrointestinal, Non-Colorectal Program, Scientific Track Leader

ASCO: Media and Technology Committee

ASCO: University Board Review Faculty

ASCO: University Tumor Board

ASCO: University Tumor Board

ASCO: Metastatic Pancreas Adenocarcinoma Guidelines Committee

Best of ASCO International Program Faculty

ASCO: University Journal Club Clinical Pathways Pharmacology

American College of Surgeons (ACOSOG) Medical Oncology Committee

All-Ireland Clinical Oncology Research Group (ICORG)

External Advisory Committee

2000

2001

2002

2002- 2004

2003- 2005

2004- 2005

2012-

2013-

2010

2014-

2014-

2005-

2015-

2003- 2008

2004-

15

Alliance: Formerly Cancer and Leukemia Group B (CALGB)

Alliance: GI Core Committee

Alliance: Upper GI/HPB Chair

American College of Radiology Imaging Network (ACRIN)

Abdominal Committee

AJCC Foregut Task Force Staging Committee

Radiation Therapy Oncology Group (RTOG), GI Committee

State-of-the-Science NIH Pancreas Think Tank

Lustgarten Foundation Pancreatic Cancer Research Consortium

NCI Pancreas Task Force: Member

NCI Pancreas Task Force: Chair

Pancreatic Cancer Action Network:

Scientific and Medical Advisory Board

NCI Pancreas Think Tank:

Pancreas Cancer Scanning the Horizon for Focused Interventions

National Pancreas Foundation (NPF): Board Member

National Comprehensive Cancer Network (NCCN):

Pancreas Panel Member

Other Activities

Chair/Member Data, Safety Monitoring Committees: Multiple Phase II/III trials

Chair/Member Steering Committees: Multiple Phase II/III trials

Chair: Pancreas Safety Advisory Committee: Sanofi Aventis

Advisory Board for multiple pancreas trials

ESMO World GI Conference Scientific Planning Committee 2015

Ad hoc Grant Reviewer

Lustgarten Foundation for Pancreatic Cancer

Swiss National Science Foundation

Australian Grant Review (National Health and Medical Research)

Alliance Co-Operative Oncology Group Grant Reviewer

AACR Pancreas Cancer Research Grants Scientific Review Committee

Cancer Research UK (CR-UK)

Irish Co-Operative Oncology Group (ICORG): External Advisory Committee

2012

2013-

2014-

2000-

2006-

2015-

2006-

2006- 2012

2007- 2008

2007

2009-

2009- 2013

2013-

2010-

16

Ontario Institute Cancer Research 2014- 2015: PanCuRx Grant $10M,

Chair, Committee

Selected Invited Lectures/ Faculty

1. Pancreatic Cancer Review. Hematology/Oncology Grand Rounds, Staten Island

University Hospital. Staten Island, NY. 1998.

2. Pharmacists GI oncology Seminar, Hoffman-La Roche Laboratories. Colorectal cancer:

Epidemiology and treatment. Nutley, NJ. 04-1998

3. Pharmacists GI oncology Seminar. Hoffman-La Roche Laboratories. Pancreatic cancer:

A challenging disease. Nutley, NJ. 04-1998

4. Clinical Investigator’s Symposium. Gemcitabine and irinotecan in refractory solid tumor malignancies. Memphis, TN. 1998

5. Pharmacists Tristate Educational Seminar. Gemcitabine and new therapies in Pancreatic

Cancer. New York, NY. 5-1998

6. Irish Society of Medical Oncology Colorectal Cancer Seminar. Colorectal Cancer:

Regional therapies for metastatic disease. Dublin, Ireland. 6-1998.

7. Pancreatic Cancer: Recent advances in staging and treatment. Vaccine Trials for

Pancreatic. New York, NY. 1998

8. Pancreatic Cancer: Lustgarten Foundation meeting. Vaccine Therapy in Pancreatic

Cancer. New York, NY 6-1999.

9. Medical Oncology Grand Rounds. Pancreatic Cancer- Treatment and new therapeutic

options. Bayonne, NJ. 1999.

10. Recent Advanced in Pancreatic Therapy. St. Francis Hospital 10 th Annual

Hematology/Oncology symposium. Hartford, CT. 10-1999.

11. Advances in the Management of Colorectal Cancer. Spanish American Medical Society

XX111rd Annual Symposium. NY, NY. 11-1999

12. Update in the Management of Pancreatic Cancer.

GI Oncology Symposium. Caracas, Venezuela. 11-1999.

13. Advances in the Management of Colorectal Cancer.

GI Oncology Symposium. Caracas, Venezuela. 11-1999.

14. Metastatic Colorectal Cancer.

Metropolitan Hospital, Medical Grand Rounds. New York, NY. 3-2000.

17

15. Advanced in Chemotherapy Agents for Pancreatic Cancer.

NYH Medical Center of Queens Lecture Series, NY. 4-2000.

16. Adjuvant therapy and treatment of locally advanced unresectable pancreatic cancer.

Pancreaticobiliary Conference, Venice, Italy. 5-2000.

17. ASCO Highlights Update: Gastrointestinal Malignancies.

New York, NY. 6-2000.

18. Treatment of Advanced Pancreatic Cancer: Community Oncology Lectureship


19. Novel Agents for Pancreatic Cancer. Barcelona, Spain. 10-2000.

20. Chemointervention for Colorectal Cancer. Duke University Women’s Oncology Cancer

Symposium. Greensboro, NC. 10-2000.

21. Management of Advanced Pancreatic Cancer. Grand Rounds. St. Vincent’s Hospital.

Staten Island, NY. 11-2000.

22. Therapeutic Advances in Pancreatic Cancer. Annual Oncology Symposium. Jupiter, Fl.

3-2001.

23. Medical Oncology Grand Rounds. Pancreatic Cancer Treatment Advances. Montefiore

Hospital. New York, NY. 3-2001.

24. Phelps Memorial Hospital Medical Oncology Tumor Board: Case Presentations and

Updates in GI oncology Talk. Tarrytown, NY. 3-2001.

25. Hematology/Oncology Grand Rounds. Gastric Cancer- Adjuvant Therapy and Molecular

Pharmacogenomics. Stamford, CT. 4-2001.

26. Gemcitabine and radiation in Pancreatic Cancer: New York Roentgen Society. New

York, NY. 4-2001.

27. Medical Oncology Grand Rounds. Updates in the management of Pancreatic Cancer.

Valhalla, NY. 4-2001.

28. ASCO GI Highlights conference. Duke University Medical Center. Raleigh-Durham, NC.

6-2001.

29. Medical Oncology Symposium. Plenary session – Two invited lectures. (1) Management of Non-operable Pancreatic Cancer. (2) Management of localized Esophageal Cancer.

Manila, Philippines. 9-2001.

30. Hematology/Oncology Grand Rounds. Treatment Advances in Pancreatic Cancer, NYU.

31. Medical Oncology Grand Rounds: New Initiatives in Pancreatic Cancer. Grand Rapids,

SD. 9-2001.


18

32. 12 th International Conference on Anti-Cancer Treatment. Member Scientific Committee and International Advisory Board. Chairperson: Pancreatic and Hepatobiliary Cancer

Section. Paris, France. 2-2002.

33. Treatment Updates in Pancreatic Cancer. Denville, NJ. 2-2002.

34. Pancreatic Cancer: Treatment Advances. Medical Oncology Grand Rounds. St. Louis

University, St. Louis, MI. 4-2002.

35. Pancreatic Cancer: Current Advances & Future Progress. Washington University, St.

Louis, MI. 4-2002.

36. Hepatobiliary Symposium (MSKCC-Naples, joint). Treatment Advances in Pancreatic

Cancer. Naples, Italy. 6-2002.

37. Hepatobiliary Symposium (MSKCC-Naples joint). New Therapeutic Advances in

Colorectal Cancer. Naples, Italy. 6-2002.

38. Treatment Algorithms for Adjuvant and Advanced Colorectal Cancer. Dublin, Ireland. 6-

2002.

39. Management of Advanced Pancreatic Adenocarcinoma. Dublin, Ireland. 9-2002.

40. Treatment of localized and extensive stage small cell lung cancer. AMNCH Medical

Grand Rounds. Dublin, Ireland. 9-2002.

41. Medical Oncology Grand Rounds, Treatment Updates in Pancreatic Cancer. American

University of Beirut (AUB). Beirut, Lebanon. 3-2003

42. Medical Oncology Grand Rounds, Advances in Pancreatic Cancer. St. George’s

Hospital. Beirut, Lebanon. 3-2003

43. Pancreatic Cancer: State of the Art Lecture. Co-Chairperson Pancreatic Symposium. Eli-

Lilly Investigator meeting. Tucson, AZ. 5-2003.

44. Adjuvant Therapy Pancreatic Cancer. Second Hepatobiliary Symposium. Treviso, Italy.

6-2003.

45. Risk Factors, Genetics and Pathogenesis of Pancreatic Cancer. Treatment Advances in

Advanced Pancreatic Cancer. Two invited lectures. 3 rd Lebanese, Syrian, Iraqi GI

Conference. Beirut, Lebanon. 9-2003.

46. Genetics, Risk Factors and Epidemiology of Pancreatic Cancer. Treatment Advances in

Pancreatic Cancer. Two invited lectures. Japanese Society of Clinical Oncology.

Sapporo, Japan. 10-2003.

47. Treatment Advances in Pancreatic Cancer. UMDNJ. Newark, NJ. 2-2004.

48. Chemotherapy for biliary cancer: Adjuvant and palliative therapy- Current Concepts.

Hepatobiliary Disease symposium, MSKCC. NY, NY. 9/04.

19

49. ASCO Annual Review. GI Medical Oncology. Cleveland Clinic, OH. 6-2005.

50. Lustgarten Foundation Annual Meeting 2005. Recently completed trials and

contemporary chemotherapy for pancreatic cancer. New York, NY. 6/05.

51. Fall Oncology Conference. Pancreas Cancer- Novel Therapies. Atlanta, GA. 10- 2005.

52. Moffitt Center GI Annual Conference. Treatment Updates in Pancreatic Cancer. Tampa,

FL. 11-2005.

53. Scripps Cancer Center Annual Conference. Targeted Therapy for Pancreas Cancer. La

Jolla, CA. 02-2006.

54. Cleveland Clinic. Hematology/Oncology Grand Rounds. State of the Art Treatment of

Pancreas Cancer. Cleveland, OH. 2-2006.

55. Middle East Medical Assembly. Treatment Advances in Pancreatic Cancer. Beirut,

Lebanon. 5-2006.

56. Irish Society of Medical Oncology Symposium. Treatment Updates & Targeted Therapy in

Pancreatic Cancer. Dublin, Ireland. 6-2006.

57. Fourth Annual GI & Thoracic Conference. New Developments in the Treatment of

Pancreatic Cancer. Hollywood, FL. 7-2006.

58. Hematology/ Oncology Grand Rounds. Bronx Lebanon Hospital. Recent Developments in the Treatment of Pancreatic Cancer. New York, NY. 7-2006.

59. Hematology/ Oncology Grand Rounds. East Stroudsburg Hospital. Treatment Updates in

Pancreatic Cancer. E. Stroudsburg, PA. 8-2006.

60. Medical Oncology Network of Pancreas Oncologists. Treatment Updates in Pancreatic

Cancer. Tokyo, Japan. 9-2006.

61. Reality Oncology (NOCR/NMCR): Gastric & GE junction Cancer: Is there a standard?

Managing recurrent colorectal cancer after adjuvant FOLFOX (2 talks). NY, NY. 9-2006.

62. Treatment Advances in Pancreatic Cancer. Grand Rounds. Columbus, OH. 9-2006.

63. Update in GE Junction & Gastric Cancer. PER. Hilton Head, SC. 9-2006.

64. New Developments in the Treatment of Pancreatic Adenocarcinoma. New Rochelle, NY.

10-2006.

65. Therapeutic Advances in Pancreatic Adenocarcinoma. Hematology-Oncology Grand

Rounds. Roswell Park Cancer Institute. Buffalo, NY. 11-2006.

66. Pancreatic Cancer: Progress- Fact or Fiction. Grand Rounds. Jamaica, NY. 12-2006.

20

67. Pancreatic Cancer: Treatment Advances. Grand Rounds. OSI Pharmaceuticals. LI, NY.

1-2007.

68. Pancreatic Cancer: Treatment Updates. Tumor Board. Mercy Medical Center. LI, NY.

1-2007.

69. Trends in GI Oncology Symposium. Treatment advances in HCC. New York, NY. 3-

2007.

70. International Society of Gastrointestinal Oncology (ISGIO). Current approaches to

Pancreatic Cancer. Arlington, VA. 3-2007.

71. Pancreatic Cancer: Progress: Fact or Fiction. Dartmouth-Hitchcock, NH. 4-2007.

72. Colorectal Cancer update: Treatment Advances. New York, NY. 4-2007.

73. ASCO Update in Upper GI Malignancies 2007. New York, NY. 8-2007.

74. Pancreatic Cancer. Treatment Updates. Fall Annual Oncology Conference, Hilton Head,

SC. 9-2007.

75. Treatment Advances in Pancreatic Adenocarcinoma. GI Cancers Annual Conference,

Columbus, OH. 10-2007.

76. Management of Inoperable Biliary Cancers. Hepatobiliary Cancers Symposium,

Cincinnati, OH. 11-2007.

77. Great Debates in GI Oncology. Pro: Non-utility of radiation in locally advanced pancreas cancer. Santa Monica, CA. 11-2007.

78. Great Debates in GI Oncology. Vaccine Therapy in GI Cancers: Current and Future prospects. Santa Monica, CA. 11-2007.

79. Hematology-Oncology Grand Rounds. Pancreatic Cancer: Progress – Fact or Fiction?

Montefiore Medical Center, NY. 1-2008.

80. American Hepatopancreaticobiliary (AHPBA) – MD Anderson Consensus Conference on

Resectable and Borderline Resectable Pancreas Cancer. Adjuvant Systemic Therapy.

Orlando, FL. 1-2008.

81. Current Trends in GI Malignancies. Is there a standard of care in the management of pancreas cancer? New York, NY. 3-2008.

82. Oncology Summit. Adjuvant & Neoadjuvant Therapy for Pancreas Cancer. Arlington, VA.

3-2008.

83. World Pancreas Symposium. Targeted Therapy in Pancreas Cancer: US perspective;;

Best Systemic Agents for Advanced Pancreas Cancer. Rome, 4-2008.

84. Innovations in the Multidisciplinary Treatment of Pancreas Cancer. University of Chicago

Pancreas Symposium. Adjuvant Therapy for Pancreas Cancer- State-of-the-Art.

21

Chicago, 9-2008.

85. International Society of Gastrointestinal Oncology (ISGIO). 5 th Annual Meeting.

Strategies for Success in the treatment of Pancreas Cancer. Virginia, 9-2008.

86. Medical Oncology Grand Rounds. Pancreas Cancer: Adjuvant & Neoadjuvant Therapy.

Karmanos Cancer Center, Detroit, 10-2008.

87. Grand Rounds/ Teaching: Pancreas cancer – Global Overview and Treatment Advances.

OSI Pharmaceuticals, New York, 4-2009.

88. AUB Basile Center Inauguration 4/09 (Lebanon). Faculty. Management of Adjuvant and locally advanced Pancreas cancer. Lebanon, 4-2009.

89. Pan Arab GI conference. Faculty. Talks (2): Esophageal cancer – Adenocarcinoma of

Squamous – does it matter? Treatment advances in early stage pancreatic cancer.

Cairo, Egypt, 5-2009.

90. Radiation Oncology Grand Rounds, MSKCC. Pancreatic Cancer – Progress – Fact or

Fiction? New York, 6-2009.

91. Best of ASCO – GI Highlights. North Shore Oncology Symposium. New York, 6-2009.

92. World GI Cancers Symposium (ESMO). Faculty. A look into the future of metastatic pancreas cancer – what’s after gemcitabine? Barcelona, Spain, 6-2009.

93. Best of ASCO official program. Faculty. GI Cancers. Beirut, Lebanon, 7/09.

94. Medical Oncology/Hematology Grand Rounds. Pancreas Adenocarcinoma – Adjuvant &

Neoadjuvant Therapy. Hackensack University, NJ, 7/09.

95. Medical Oncology/Hematology Grand Rounds. Current Treatment Options for Pancreas

Adenocarcinoma. Dallas, TX, 8/09.

96. Southern Foregut Pancreas Cancer Symposium. Faculty. Adjuvant & Neoadjuvant

therapy for pancreas cancer. Treatment of Metastatic Pancreas Cancer. Management of

Pancreas Neuroendocrine Tumors. (3 talks). Cork, Ireland, 10/09.

97. Upper GI Cancers Symposium. Faculty. Pancreas cancer – treatment advances.

Washington, 10/09.

98. GI Cancers Meeting. Faculty. Biliary cancer – clinical presentation and current treatment

options. Sante Fe, NM, 12/09.

99. Building Better Strategies in the Management of Pancreas Adenocarcinoma. Faculty.

Gastrointestinal Cancers Symposium. Orlando, Fl, 01/10.

100. Best of ASCO. GI Faculty. Non-Colorectal Upper GI Malignancies. Lebanon, 06/10.

101. Peruvian Society of Medical Oncology. Faculty. Treatment Advances in Pancreas

Adenocarcinoma. Medical Management of Pancreas Neuroendocrine Tumors. Cuzco,

22

Peru, 08/10.

102. Invited Grand Rounds. The Quality Care Continuum in Advanced Pancreas Cancer.

Stamford, CT. 09/10.

103. MSKCC Pancreas Neoplasms Symposium. Faculty/Co-Director. New Developments in

Treating Pancreas Cancer. MSKCC, NY, 10/10.

104. Medical Oncology Grand Rounds. Pancreas Cancer: Current Controversies and New

Directions. Jefferson, PA. 10/10.

105. Irish Society Medical Oncology. Pancreas Cancer: Novel Therapeutics. Dublin, Ireland,

10/10.

106. Lebanese Society Medical Oncology (LSMO)-MSKCC Joint Symposium. Faculty.

Pancreas Adenocarcinoma – Treatment Options. Lebanon, 12/10.

107. GEMCAD – Spanish Co-operative Oncology Group. Faculty. Pancreas Adenocarcinoma

– Emerging Directions – Adjuvant and Neoadjuvant Therapy. Barcelona, 03/11.

108. Pancreatic Cancer Action Network. Public Lecture. New Developments in the Treatment

of Pancreas Adenocarcinoma. Washington DC, 03/11.

109. Great Debates in GI Oncology. Faculty – 3 invited lectures on Pancreas

Adenocarcinoma. New York, NY, 03/11.

110. American Society Clinical Oncology (ASCO). Faculty. Educational session chair. Moving the bar in upper GI malignancies: clinically meaningful or just statistically significant?

Chicago, IL, 06/11.

111. Hepatopancreaticobiliary symposium. Faculty. Adjuvant and Neoadjuvant Therapy for

Pancreas Adenocarcinoma. Biliary Cancers: New Horizons. Treviso, Italy, 06/11.

112. World GI ESMO Congress. Faculty. New Therapeutic Directions in Pancreas and Biliary

Malignancies. Barcelona, Spain, 06/11.

113. Pancreas Symposium. Royal Marsden. Faculty. Biomarker Driven Therapy in Pancreas

Adenocarcinoma. London, England, 06/11

114. Best of ASCO International Program. Gastrointestinal Oncology Faculty. Lebanon,

07/11.

115. Japanese Society of Medical Oncology (JSMO). 9 th Annual Meeting. Invited Faculty:

New Treatment Innovations In Pancreas Adenocarcinoma. Discussant Plenary Session:

GEST Randomized Phase III Trial in Advanced Pancreas Adenocarcinoma. Yokohama,

116. Trinity Medical School Tercentenary. Faculty: Medical Management of Colorectal Liver

Metastases. Dublin, Ireland, 09/11.

Japan, 07/11.

23

117. Cancer Symposium. Faculty: Pancreas Adenocarcinoma: New Therapeutic Directions.

Syracuse. 09/11.

118. The Claude Smith Memorial Lectureship. Invited Lecture in Pancreas Adenocarcinoma.

John’s Hopkins’s Cancer Center. Baltimore, MD 09/11.

119. Research To Practice. Invited Faculty. Gastrointestinal Malignancies. Florida, 10/11.

120. Public lecture. Pancreatic Cancer Action Network. Understanding Pancreas

Adenocarcinoma. New York, NY. 10/11.

121. Hong Kong International Cancer Congress. Faculty. New Directions in the treatment of

Pancreas Adenocarcinoma. Hong Kong, 11/11.

122. Chemotherapy Foundation. Faculty. Moving Forward in the Era of FOLFIRINOX. New

York, NY. 11/11.

123. Emerging Treatment Options for Pancreas Adenocarcinoma. Gastrointestinal Cancers

Symposium. San Francisco, CA, 01/12.

124. Great Debates in Gastrointestinal Cancers. Future Directions in the Strategic Targeting of

Pancreas Adenocarcinoma. Faculty. New York, NY, 03/12.

125. Demystifying Futility in Pancreatic Cancer. Invited Faculty. Cancer Research UK,

Cambridge Research Institute. United Kingdom, 05/12.

126. Personalized Medicine: Fact or Fiction in Pancreas Cancer. The Lunenfield Research

Institute International Symposium. Invited Faculty. Toronto, 05/12.

127. Best of ASCO International Program. Gastrointestinal Oncology Faculty. Lebanon,

06/12.

128. World GI ESMO Congress. New Agents for Pancreas Adenocarcinoma. Invited Faculty.

Barcelona, Spain, 06/12.

129. CSCO (Chinese Society Clinical Oncology). Pancreas Adenocarcinoma: Current & New

Directions. Invited Faculty. Beijing, China, 09/12.

130. International Society of Gastrointestinal Cancer (ISGIO). Moderator Pancreas Cancer

session. Washington, 09/12.

131. National Comprehensive Cancer Network (NCCN). Faculty. Pancreas cancer. Current strategies and new directions. Duke, SC, 11/12.

132. Gastroenterology Teaching Day. Current directions in pancreas cancer. Binghamton,

NY. 11/12.

133. MSKCC CME: Advances in the diagnosis and treatment of primary liver cancer. Faculty.

Current therapies in the adjuvant and palliative setting for biliary cancers. New York, NY,

11/12.

24

134. Office of Clinical Research, MSKCC. Pancreas Adenocarcinoma: New Treatment

Directions. New York, NY 01/13.

135. MSKCC Cancer Education Lecture: Pancreas Adenocarcinoma. New Directions. New

York, NY 02/13.

136. Hematology-Oncology Grand Rounds MSKCC. Pancreas Adenocarcinoma. MSKCC-

Emerging Research Directions. New York, NY 03/13.

137. Great Debates. Faculty. Lecture: Emerging Therapies in Pancreas Adenocarcinoma:

Abundance of Targets, Few Trials. New York, NY 04/13.

138. MSKCC-AUB Oncology Course – Co-Director 2013. Multiple Lectures: Pancreas, Biliary,

IRB. Beirut, Lebanon, 06/13.

139. Adjuvant & Neoadjuvant Therapy Pancreas Adenocarcinoma. Treatment Advances in

Metastatic Pancreas Adenocarcinoma. Cancer Congress. Sao Paolo, Brazil, 09/13.

140. Pancreas Adenocarcinoma: Real Progress or Not? Irish Cancer Symposium. Dublin,

Ireland, 10/13.

141. Lustgarten Foundation Annual Scientific meeting. Banbury, NY. 10/13.

BRCA-related pancreas cancer. New directions in therapy.

142. First and Second-Line Therapy in Pancreas Adenocarcinoma. Chemotherapy

Foundation, New York, NY 11/13.

143. Biology and Molecular Pathology Pancreas Adenocarcinoma. Educational Concepts

Program. New York, NY 11/13.

144. AHPBA Consensus Conference: Bile Duct Cancers. Faculty. San Francisco, CA. 01/14.

Intrahepatic Cholangiocarcinoma: Adjuvant therapy.

145. Gastrointestinal Cancers Symposium. Faculty. Emerging Therapies in Pancreas

Adenocarcinoma. San Francisco, NY, 01/14.

146. Gastrointestinal Cancers Symposium. Meet The Professor Sessions (2). Adjuvant

Therapy and Treatment of Metastatic Pancreas Adenocarcinoma. San Francisco, CA.

01/14.

147. Peerview Press U Penn Symposium. Novel Therapeutics for Pancreas Adenocarcinoma.

San Francisco, CA. 01/14.

148. Beaujon Hepatopancreaticobiliary Conference. Emerging Treatment Directions in

Pancreas Adenocarcinoma. Paris, France. 02/14.

149. MSKCC Board Review Course. NY, NY. 03/14. Pancreas adenocarcinoma and neuroendocrine malignancies.

25

150. National Pancreas Symposium. Fellows Teaching Conference. Baltimore, MD. 04/14.

Faculty/Mentor for Pancreas malignancies.

151. Holling’s Cancer Center. Invited Reviewer for Pancreas program. SC. 04/14. Lecture:

Novel Therapeutics in Pancreas Cancer.

152. MSKCC-Salzburg Teaching Course: GI Malignancies. 4 lectures: Pancreas,

Neuroendocrine, Small bowel and Esophagogastric Cancers. Salzburg, 05/14.

153. AACR Special Conference on Pancreas Conference, New Orleans, 05/14. Plenary session: BRCA-related Pancreas adenocarcinoma. New directions in therapy.

Faculty and Session Chair.

154. Montreal Cancer Conference. Quebec. 05/14. Invited Faculty. New developments in the treatment of metastatic pancreas adenocarcinoma.

155. PeerView Press PennState Symposium, Chicago, 05/14. Invited Faculty. Emerging

therapies for pancreas adenocarcinoma.

156. ESMO World Congress on Gastrointestinal Cancers. Barcelona, Spain. 06/14.

Invited Faculty. ‘What is the optimal treatment for advanced pancreas adenocarcinoma?’.

157. Pancreas Cancer – Current Developments. Special Conference. Chicago, 09/14.

158. Pancreas Cancer: Board Review. Athens, 01/15.

159. Great Debates Faculty. ‘Building on cytotoxic backbones – a platform for novel

therapeutics in pancreas adenocarcinoma’. New York, NY, 03/15.

160. Pancreas Adenocarcinoma: Novel Approaches. Columbia University Grand Rounds.

New York, NY, 04/15.

161. Oncology Nursing Symposium Plenary. Faculty Chair: Pancreas Adenocarcinoma.

Orlando, FL, 04/15.

162. National Pancreas Foundation. Fellow’s Teaching Conference. Faculty/Mentor for

Pancreas Malignancies. Baltimore, MD, 04/15.

163. TRM: Pancreas Cancer: New Directions in Adjuvant and Neoadjuvant Therapy. Chicago,

IL, 05/15.

164. Hartford Sullivan Pancreas Symposium. Pancreas Adenocarcinoma: Novel

Therapeutics. Hartford, CT, 05/15.

165. Middle East Medical Assembly. Pancreas Adenocarcinoma: Current and Future

Directions. Beirut, Lebanon, 05/15.

166. Faculty: American Society of Clinical Oncology. Highlights of the Day;; Other

responsibilities.

26

167. Gastrointestinal Cancer Conference. Pancreas Adenocarcinoma: 2 lectures;;

Epidemiology and genetics;; Novel Therapeutics. Tyler, Texas, 06/15.

168. Hepatopancreaticobiliary Symposium. Faculty. Cholangiocarcinoma: New Systemic

Directions. Treviso, Italy, 06/15.

169. Best of ASCO. Faculty. Non-Colorectal GI. Boston, 07/15.

170. Treatment Advances in Pancreas Adenocarcinoma. Chinese Society Clinical Oncology

(CSCO). Keynote Speaker. 09/15.

171. Terry Fox Translational Pancreas Scientific Workshop. Speaker: DNA Damage

Response Targeting. 09/15.

Pending

Faculty: Mayo Clinic Pancreatic Cancer Conference, Scottsdale, AZ, 10/15

John’s Hopkins Cancer Center, 11/15

Faculty: GI Cancers Symposium, Fred Hutchinson Cancer Center, Keynote Speaker, 03/16

Editorial Positions/ Reviewer Positions

Title

Reviewer

Reviewer

Reviewer

Reviewer

Reviewer

Title of Journal

British Journal of Cancer

Cancer Research

Cancer

Cancer Investigation

Clinical Cancer Research

Digestive Diseases and Sciences

Dates Held

2003-

2002-

1999-

2003-

2003-

2004- Reviewer

Editorial

Board

Reviewer

Reviewer

Editorial

Board

Reviewer

Editor

Reviewer

Editorial

Board

Reviewer

Reviewer

Reviewer

Reviewer

Reviewer

Reviewer

Reviewer

Reviewer

Index Colorectal Cancer and Reviews

Investigational New Drugs

Journal of Clinical Oncology (JCO)

Journal of Clinical Oncology (JCO)

Journal of Surgical Oncology (JSO)

Lebanese Medical Journal

Oncology

The Oncologist

Pancreas

Cancer Chemotherapy & Pharmacology

Expert Opinion on Pharmacotherapy

Clinical Colorectal Cancer Research

Journal of Gastrointestinal & Liver Diseases

Journal of Cancer Research & Therapeutics

Journal of the American Medical Association (JAMA)

Clinical Colorectal Cancer

2001- 2006

2004-

2002-

2014-

2004-

2004-

2004-

2009-

2004-

2007-

2007-

2007-

2008-

2008-

2008-

2007-

27

Reviewer

Reviewer

Editorial

Board

Reviewer

Reviewer

Reviewer

Reviewer

Reviewer

Reviewer

Reviewer

Editor-in

Chief

Reviewer

Reviewer

Reviewer

Reviewer

Reviewer

Reviewer

Reviewer

Reviewer

Reviewer

Reviewer

Reviewer

Reviewer

Reviewer

Reviewer

Reviewer

European Journal of Cancer (EJC)

Hepatology

World Journal of Hepatology

Current Opinion: Investigational Drugs

Journal of Clinical Gastroenterology

Current Cancer Drug Targets

The Lancet Oncology

Annals of Surgery

Oncology (Karger)

Annals of Surgical Oncology

Gastrointestinal Cancer: Targets and Therapy

Journal of Geriatric Oncology

Clinical Investigation

Journal of Pancreas

Onkologie

American Journal of Epidemiology

Pancreatology

Pharmacogenomics

Gastroenterology

Journal of the National Cancer Institute (JNCI)

Future Oncology/Future Medicine

New England Journal of Medicine (NEJM)

Hepatobiliary & Pancreatic Diseases International

Drugs

Journal of Clinical Investigation

JNCCN

2009-

2009-

2009-

2009-

2009-

2010-

2010-

2010-

2010-

2010-

2010- Present

L. BIBLIOGRAPHY

1. Peer Reviewed Articles

1. J.E. Gillan, C. Curran, E.M. O’Reilly , S.F. Cahalane, A.R. Unwin. Abnormal patterns of pulmonary neuroendocrine cells in victims of sudden infant death syndrome. Pediatrics.

1989, 84: 828-834.

2. E.M. O’Reilly , P.W. Chambers, D.K. Chambers. Membrane bound acetylcholinesterase on mouse red blood cells. Ind Pharm J. 1989 (6): 27-29.

3. E.M. O’Reilly , J.P. Crown. Second cancers complicating Hodgkin’s disease. Ann

Oncol. 1996 Apr;;7(4): 405-8.

4. E.M. O’Reilly , D.H. Ilson, L.B. Saltz, R. Heelan, L. Martin, D.P. Kelsen. A phase II trial of interferon alfa-2a and carboplatin in patients with advanced malignant mesothelioma.

Cancer Invest. 1999;;17(3): 195-200.

5. F. Fata, E.M. O’Reilly , D. Ilson, D. Pfister, D. Leffel, D.P. Kelsen, G.K. Schwartz, E.S.

Casper. Paclitaxel in the treatment of angiosarcomas of the scalp. Cancer.1999 Nov

2011-

2011-

2011-

2011-

2011-

2012-

2012-

2012-

2012-

2013-

2012-

2014-

2014-

2014-

2014-

28

15;;86(10):2034-7.

6. F. Fata, I. Ron, N. Kemeny, E. O’Reilly, D. Klimstra, D. Kelsen. Fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma. Cancer. 1999 Oct

1;;86(7):1129-34.

7. D. Ilson, L. Saltz, P. Enzinger, Y. Huang, A. Kornblith, M. Gollub, E. O’Reilly , G.

Schwartz, J. DeGroff, G. Gonzalez, D. Kelsen. A phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol. 1999 Oct;;17(10):3270-5.

8. P. Sanz-Altamira, E.M. O’Reilly , K.E. Stuart, S. Lynn Raeburn, C. Steger, N.E. Kemeny,

L.B. Saltz. A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma.

Ann Oncol. 2001 Apr;;12(4):501-4.

9. A.T. Culliford, 4 th , A.D. Brooks, S. Sharma, L.B. Saltz, G.K. Schwartz, E.M. O’Reilly ,

D.H. Ilson, N.E. Kemeny, D.P. Kelsen, J.G. Guillem, W.D. Wong, A.M. Cohen, P.B. Paty.

Surgical debulking and intraperitoneal chemotherapy for established peritoneal metastases from colon and appendix cancer. Ann Surg Oncol. 2001, 8(10):787-795.

10. S. Sharma, N. Kemeny, G.K. Schwartz, D. Kelsen, E. O’Reilly , D. Ilson, J. Coyle, R.L.

De Jager, M.P. Ducharme, S. Kleban, E. Hollywood, L.B. Saltz. Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks. Clin Cancer Res. 2001, 7(12):3963-3970.

11. E.M. O’Reilly , K.E. Stuart, P.M. Sanz-Altamira, G.K. Schwartz, C.M. Steger, L. Raeburn,

N.E. Kemeny, D.P. Kelsen, L.B. Saltz. A phase II study of irinotecan in patients with advanced hepatocellular carcinoma. Cancer. 2001 Jan 1;;91(1):101-5.

12. G.K. Schwartz, D. Ilson, L. Saltz, E. O’Reilly , W. Tong, P. Maslak, J. Werner, P.

Perkins, M. Stoltz, D. Kelsen. Phase II study of the Cyclin-Dependent Kinase Inhibitor

Flavopiridol Administered to patients with advanced gastric carcinoma. J Clin Oncol.

2001 Apr 1;;19(7):1985-92.

13. Nash, G.M., Saltz, L.B., Kemeny, N.E., Minsky, B.,Sharma, S., Schwartz, G.K., Ilson,

D.H., O'Reilly, E.

, Kelsen, D.P., Nathanson, D.R., Weiser, M., Guillem, J. G., Wong,

W.D., Cohen, A.M., Paty, P.B. Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV disease. Ann Surg Oncol. 2002

Dec;;9(10):954-60.

14. Sharma, S., Kemeny, N., Kelsen, D.P., Ilson, D., O'Reilly, E ., Zaknoen, S., Baum, C.,

Statkevich, P., Hollywood, E., Zhu, Y., Saltz, L.B. A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan. Ann Oncol. 2002

Jul;;13(7):1067-71.

15. G.K. Schwartz, E. O’Reilly , D. Ilson, L. Saltz, S. Sharma, W. Tong, P. Maslak, M. Stolz,

L. Eden, S. Endres, J. Barazzoul, D. Spriggs, D. Kelsen. Phase I study of the cyclin- dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J Clin Oncol. 2002 Apr 15;;20(8):2157-70.

29

16. C. A. Azzoli, V.A. Miller, K.K. Ng, L.M. Krug, M.L. Hensley, E.M. O’Reilly , R.J. Mueller,

M.G. Kris. Gemcitabine-induced peripheral edema: A report on 15 cases and review of the literature. Am J Clin Oncol. 2003 Jun;;26(3):247-51.

17. S.E. Anderson, E.M. O’Reilly , D.P. Kelsen, D.H. Ilson. Phase II trial of 96 hour paclitaxel in previously treated patients with advanced esophageal cancer. Cancer

Invest. 2003;;21(4):512-6.

18. G.M. Nash, L.B. Saltz, N.E. Kemeny, B.D. Minsky, S. Sharma, G.K. Schwartz, D.H.

Ilson, E.M O’Reilly , D.P. Kelsen, D.R. Nathanson, M. Weiser, J.G. Wong, A.M. Cohen,

P.B. Paty. Radical resection of rectal cancer therapy in patients with stage IV disease.

Ann Surg Oncol. 2003, Vol 9(10):954-960.

19. D.H. Ilson, M. Bains, D.P. Kelsen, E. O’Reilly , M. Karpeh, D. Coit, V. Rusch, M. Gonen,

K. Wilson, B.D. Minsky. Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer. J Clin

Oncol. 2003 Aug 1;;21(15):2926-32.

20. Abou-Alfa, GK;; Rowinsky, EK;; Patt, YZ;; Schwartz, GK;; Kelsen, DP;; Sharma, S;; Siegel,

E;; Becerra, CR ;; Eckhardt, SG ;; Feit, K ;; De Jager, R ;; O'Reilly, EM . A Phase II Study of Intravenous Exatecan Administered Daily for Five Days, Every Three Weeks to

Patients with Biliary Tract Cancers. Am J Clin Oncol. 2005 Aug;;28(4):334-9.

21. Shah, M.A., Kortmansky, J., Motwani, M., Drobnjak, M., Gonen, M., Yi, S., Weyerbacher,

A., Cordon-Cardo, C., Lefkowitz, R., Brenner, B., O'Reilly, E.

, Saltz, L., Tong, W.,

Kelsen, D.P., Schwartz, G.K. A phase I clinical trial of the sequential combination of

irinotecan followed by flavopiridol. Clin Cancer Res. 2005 May 15;;11(10):3836-45.

22. Schwartz, G.K., Weitzman, A., O'Reilly, E ., Brail, L., de Alwis, D.P., Cleverly, A., Barile-

Thiem, B., Vinciguerra, V., Budman, D.R. Phase I and pharmacokinetic study of

LY293111, an orally bioavailable LTB4 receptor antagonist, in patients with advanced solid tumors. J Clin Oncol. 2005 Aug 10;;23(23): 5365-73. Epub 2005 Jun 6.

23. Kortmansky, J., Shah, M.A., Kaubisch, A., Weyerbacher, A., Yi, S., Tong, W., Sowers,

R., Gonen, M., O'Reilly, E.

, Kemeny, N., Ilson, D.I., Saltz, L.B., Maki, R.G., Kelsen,

D.P., Schwartz, G.K. Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors. J Clin Oncol. 2005 Mar 20;;23(9):1875-84. Epub 2005 Feb

7.

24. Abou-Alfa, GK ;; Letourneau, L ;; Harker, WG ;; Modiano, M ;; Hurwitz, H ;; Tcehekmedyian,

NS ;; Feit, K ;; Ackerman, J ;; DeJager, RL ;; Eckhardt, SG ;; O'Reilly, EM . A Randomized

Phase III Study of Exatecan and Gemcitabine Compared to Gemcitabine Alone in

Untreated Advanced Pancreatic Cancer. J Clin Oncol. 2006 Sep 20;;24(27):4441-7.

25. Shah, M., Ramanathan, R., Ilson, D, Levnor, A., D’Adamo, D., O’Reilly, E ., Tse, A.,

Trocola, R., Schwartz, L., Capanu, M., Schwartz, M., Kelsen, D. A multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or

gastroesophageal junction adenocarcinoma. J Clin Oncol. 2006 Nov 20;;24(33):5201-6.

30

26. Duffy, A., Kortmansky, J., G.K. Schwartz, Capanu, M., S. Puleio, B. Minsky, L. Saltz,

D.P. Kelsen, E.M. O’Reilly . A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced non-operable pancreas adenocarcinoma. Annals

Oncol. 2008, 19:86-91.

27. M.N. Fornier, D. Rathkopf, M. Shah, S. Patil, E. O’Reilly , A.N. Tse, C. Hudis, R.

Lefkowitz, D.P. Kelsen, G.K. Schwartz. Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors. Clin Cancer Res. 2007

Oct 1;;13(19):5841-6.

28. R. Carvajal, A. Tse, M.A. Shah, R.A. Lefkowitz, M. Gonen, L.Gilman-Rosen, J.

Kortmansky, D.P. Kelsen, G.K. Schwartz, E.M. O'Reilly . A Phase II Study of flavopiridol

(Alvocidib) in combination with docetaxel in refractory, metastatic pancreas cancer (NCI

#6366). Pancreatology. 2009;;9(4):404-9. Epub 2009 May 19.

29. A. Duffy, M. Capanu, G.K. Abou-Alfa, D. Huitzil, W. Jarnagin, Y. Fong, M. D'Angelica,

R.P. DeMatteo, L.H. Blumgart, E.M. O'Reilly . Gallbladder Cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Center. J Surg Oncol. 2008 Dec

1;;98(7):485-9.

30. Tse, A.N., Klimstra, D.S., Gonen, M., Shah, M., Sheikh, T., Sikorski, R., Carvajal, R.,

Mui, J., Tipian, C., O'Reilly, E ., Chung, K., Maki, R., Lefkowitz, R., Brown, K., Manova-

Todorova, K., Wu, N., Egorin, M.J., Kelsen, D., Schwartz, G.K. A phase 1 dose- escalation study of irinotecan in combination with 17-allylamino-17- demethoxygeldanamycin in patients with solid tumors. Clin Cancer Res. 2008 Oct

15;;14(20):6704-11.

31. Endo I, Gonen M, Yopp AC, Dalal KM, Zhou Q, Klimstra D, D'Angelica M, DeMatteo RP,

Fong Y, Schwartz L, Kemeny N, O'Reilly E , Abou-Alfa GK, Shimada H, Blumgart LH,

Jarnagin WR. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008 Jul;;248(1):84-96.

32. L.H. Tang, J.Shia, R.A. Soslow, D. Dhall, W.D. Wong, E. O'Reilly , J. Qin, P. Paty, M.R.

Weiser, J. Guillem, L. Temple, L.H. Sobin, D.S. Klimstra. Pathologic classification and clinical behavior of the spectrum of goblet cell carcinoid tumors of the appendix. Am J

Surg Pathol. 2008 Oct;;32(10):1429-43.

33. G.Y. Ku, D.H. Ilson, L.H. Schwartz, M. Capanu, E. O'Reilly , M.A. Shah, D.P. Kelsen,

G.K. Schwartz. Phase II trial of sequential paclitaxel and 1 hour infusion of bryostatin-1 in patients with advanced esophageal cancer. Cancer Chemother Pharmacol. 2008

Oct;;62(5):875-80. Epub 2008 Feb 13.

34. Tew, W.P., Radovich, D., O'Reilly, E., Schwartz, G., Schrag, D., Saltz, L.B., Kelsen,

D.P., Kepler, S., Ilson, D.H. Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer. Invest New Drugs. 2009 Aug;;27(4):366-

73. Epub 2008 Oct 28.

35. Murugesan, S.R., King, C.R., Osborn, R., Fairweather, W.R., O'Reilly, E.M.

, Thornton,

M.O., Wei, L.L. Combination of human tumor necrosis factor-alpha (hTNF-alpha) gene delivery with gemcitabine is effective in models of pancreatic cancer. Cancer Gene

31

Ther. 2009 Nov;;16(11):841-7. Epub 2009 May 15.

36. R.A. Abrams, A.M. Lowy, E.M. O'Reilly , R.A. Wolff, V.J. Picozzi, P.W.T. Pisters.

Combined Modality Treatment of Resectable and Borderline Resectable Pancreas

Cancer: Expert Consensus Conference. Ann Surg Oncol, 2009 Jul;;16(7):1751-6. Epub

2009 Apr 24.

37. Ku, G.Y., O'Reilly, E.M

., Saltz, L.B., Schrag, D., Maki, R.G., Kelsen, D.P., Ilson, D.H.

Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in

advanced solid tumors. Cancer Invest. 2009 May;;27(4):402-6.

38. P.A. Philip, M. Mooney, D. Jaffee, G. Eckhardt, M. Moore, N. Meropol, L. Emens, E.M.

O’Reilly , M. Korc, L. Ellis, J. Benedetti, M. Rothenberg, C. Willett, M. Tempero, A. Lowy,

J. Abbruzzese, D. Simeone, S. Hingorani, J. Berlin, J. Tepper. Consensus report of NCI

Clinical Trials Planning Meeting on Pancreas Cancer Treatment. J Clin Oncol. 2009 Nov

20;;27(33):5660-9. Epub 2009 Oct 26.

39. A. Duffy, M. Capanu, R. Kurtz, S. Olson, E. Ludwig, D. Klimstra, E.M. O’Reilly .

Pancreatic adenocarcinoma in a young patient population – 12-year experience at

Memorial Sloan-Kettering Cancer Center. J Surg Oncol. 2009 Jul 1;;100(1):8-12.

40. P.A. Philip, J. Benedetti, C. Corless, R. Wong, E.M. O’Reilly , P.J. Flynn, K.M. Rowland,

J.N. Atkins, B. Mirtsching, S. Rivkin, A. Khorana, B. Goldman, C. Fenoglio, J.

Abbruzzese, C.D. Blanke. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: SWOG- directed Intergroup trial S0205. J Clin Oncol. 2010 Aug 1;;28(22):3605-10. Epub 2010

Jul 6.

41. C.M. Moinpour, N. Vaught, B. Goldman, M.W. Redman, P.A. Philip, B. Millwood, J.N.

Atkins, S.M. Lippman, T.E. Seay, P.J. Flynn, E.M. O’Reilly , K.M. Rowland, R. Wong, J.

Benedetti, C.D. Blanke. Pain and emotional well-being outcomes in Southwest

Oncology Group-directed Intergroup trial S0205: A phase III randomized, open-label study comparing gemcitabine plus cetuximab (IMC-225) versus gemcitabine as first line therapy of patients with advanced pancreas cancer. J Clin Oncol. 2010 Aug

1;;28(22):3611-6. Epub 2010 Jul 6.

42. Olson, S.H., Chou, J.F., Ludwig, E., O'Reilly, E ., Allen, P.J., Jarnagin, W.R., Bayuga, S.,

Simon, J., Gonen, M., Reisacher, W.R., Kurtz, R. C. Allergies, obesity, other risk factors

and survival from pancreatic cancer. Int J Cancer. 2010 Feb 8. Doi 10.1002/ijc.25240.

43. G.K. Abou-Alfa, P.B. Chapman, J. Feilchenfeldt, M.F. Brennan, M. Capanu, B. Gansukh,

G. Jacobs, A. Levin, D. Neville, D.P. Kelsen, E.M. O’Reilly . Targeting mutated K-ras in pancreatic adenocacinoma using an adjuvant vaccine. Am J Clin Oncol. 2011 Jun;;

34(3): 321-325.

44. F.D. Huitzil Melendez, M. Capanu, E.M. O’Reilly , A. Duffy, L.B. Saltz, G.K. Abou-Alfa.

Advanced hepatocellular carcinoma: Which staging systems predict prognosis. J Clin

Oncol. 2010 Jun 10;;28(17):2889-95. Epub 2010 May 10.

45. V.J. Picozzi, R.A. Abrams, P.A. Decker, W. Traverso, E.M. O’Reilly , E. Greeno, R.C.

Martin, L.S. Wilfong, M.L. Rothenberg, M.C. Posner, P.W.T. Pisters. ACOSOG Z05031:

32

A multicenter phase II trial for adjuvant therapy of resected pancreatic cancer using cisplatin, 5-FU and alpha-interferon-based concurrent chemoradiation. Ann Oncol. 2011

Feb;;22(2):348-54. Epub 2010 Jul 29.

46. H.L. Kindler, D. Niedzwiecki, D. Hollis, S. Sutherland, D. Schrag, H. Hurwitz, F.

Innocenti, M. Mulcahy, E.M. O’Reilly , H. Hurwitz, T. Wozniak, B.R. Tan, P. Bhargava,

R.L. Schilsky, R.M. Goldberg. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: A phase III trial of the Cancer and Leukaemia Group B. J Clin Oncol. 2010 Aug 1;;28(22):3617-22. Epub

2010 Jul 6.

47. E.M. O’Reilly , D. Niedzwicki, M. Hall, D. Hollis, T. Bekaii-Saab, T. Pluard, K. Douglas,

H.L. Kindler, R.L. Schilsky, R.M. Goldberg. A Cancer and Leukemia Group B Phase II

Study of Sunitinib Malate in Patients with Previously Treated Metastatic Pancreatic

Adenocarcinoma (CALGB 80603). Oncologist. 2010 Dec 15. DOI

10.1634/theoncologist.2010-0152.

48. S.H. Olson, T.M. Layne, J.A. Simon, E. Ludwig, E. O’Reilly, P.J. Allen, R.C. Kurtz.

Studying Cancer in Minorities: A look at the Numbers. Cancer. 2011: 117(12): 2762-

2769.

49. A.E. Epstein, G.A. Soff, M. Capanu, C. Crosbie, M.A. Shah, D.P. Kelsen, B. Denton, S.

Gardos, E.M. O’Reilly . Analysis of Incidence and Clinical Outcomes in Patients with

Thromboembolic Events and Invasive Exocrine Cancer at Memorial Sloan-Kettering

Cancer Center. Cancer. 2012 Jun 15;;118(12):3053-61. doi: 10.1002/cncr.26600. Epub

2011 Oct 11.

50. M.A. Lowery, D.P. Kelsen, Z.K. Stadler, Y.Y. Janjigian, K.H. Yu, M. Ludwig, D.R.

D’Adamo, E. Salo-Mullen, M.E. Robson, P.J. Allen, R. Kurtz, E.M. O’Reilly . An

Emerging Entitty: Pancreatic Adenocarcinoma Associated with a Known BRCA

Mutation: Clinical Descriptors, Treatment Implications and Future Directions.

Oncologist . 2011;;16(10):1397-402. Epub 2011 Sep 20.

51. A. Roberts, M. Campa, E. Gottlin, C. Jiang, K. Owzar, H. Kindler, A. Venook, R.

Goldberg, E.M. O’Reilly , E. Patz, Jr. Identification of Potential Prognostic Biomarkers in

Patients with Untreated, Advanced Pancreatic Cancer from a Phase III Trial (CALGB

80303). Cancer. 2012. Jan 15;;118(2):571-8. doi: 10.1002/cncr.26270. Epub 2011 Jun

28.

52. N.T. Sklarin, S. Granovsky, E.M. O’Reilly , A. Zelenetz. Electronic Chemotherapy Order

Entry: A Major Cancer Center’s Implementation. J Oncol Practice. 2011: 7(4): 213-218.

53. M.A. Lowery, D.S. Klimstra, J. Shia, K. Yu, P. Allen, M. Brennan, E.M. O’Reilly . Acinar

Cell Carcinoma of the Pancreas: New Genetic and Treatment Insights into a Rare

Malignancy . Oncologist. 2011. DOI 10.1634/tehonocologist.2011-0321.

54. C. O’Neill, C. Swartz, E.M. O’Reilly , J. LaFemina, M. Henman, E. Elin. Costs and

Trends in Pancreatic Cancer Treatment . Cancer. 2012 Mar 15 doi 10.1002/cncr.27490.

55. A.S. Epstein, A.E. Volantes, E.M. O’Reilly . Building on Individual, State and Federal

Initiatives for Advance Care Planning, an Integral Component of Palliative and End-Of-

33

Life Cancer Care. J Oncology Practice. 2011 (7)6: 355-359.

56. P. Wagner, D. Jones, A. Aronova, J. Shia, Weiser, M.R., Temple, L.K., Chung, K.Y.,

E.M. O’Reilly , D.P. Kelsen, Paty, P.B., Nash, G.M. Early post-operative intraperitoneal chemotherapy following cytoreductive surgery for appendiceal mucinous neoplasms and

isolated peritoneal metastasis. Dis Colon Rec. 2012 Apr;; 55(4): 407-415.

57. A.E. Volandes, T. Levin, S. Slovin, R. Carvajal, E.M. O’Reilly , M.L. Keohan, M.

Theodolou, M. Dickler, J.F. Gericitano, M. Morris, A. Epstein, A. Naka-Blackstone, E.

Walker-Corkery, Y. Chang, A. Noy. Augmenting advance care planning in poor prognosis cancer with a video decision aid: a preintervention-postintervention study.

Cancer. 2012 Jan 17. DOI 10.1002/cncr.27423.

58. J. Winter, L.H. Tang, D.S. Klimstra, M.F. Brennan, M. D’Angelica, R.P. DeMatteo, Y.

Fong, W.R. Jarnagin, E.M. O’Reilly , P. Allen. Failure Patterns in Resected Pancreas

Adenocarcinoma: Lack of Predicted Benefit to SMAD4 Expression. Ann Surg. 2013

Aug;;258(2):331-5. doi: 10.1097.

59. A.E. Epstein, A. Volandes, L.Y. Chen, K.A. Gary, Y. Li, P. Agre, T.T. Levin, D.L. Reidy,

R.D. Meng, N.H. Segal, K. Yu, G.K. Abou-Alfa, Y.Y. Janjigian, D.P. Kelsen, E.M.

O’Reilly . A Randomized Controlled Trial of Cardiopulmonary Resuscitation Video in

Advance Care Planning for Progressive Pancreas and Hepatobiliary Cancer Patients. J

Palliat Med. 2013 Jun;;16(6):623-31. doi: 10.1089.

60. Bickenback, K.A., Gonen, M., Tang, L.H., O’Reilly, E ., Goodman, K., Brennan, M.F.,

D’Angelica, M.I., DeMatteo, R.P., Fong, Y., Jarnagin, W.R., Allen, P.J. Downstaging in

Pancreatic Cancer: A Matched Analysis of Patients Resected Following Systemic

Treatment of Initially Locally Unresectable Disease. Ann Surg Oncol.

2012

May;;19(5):1663-9. doi: 10.1245.

61. B.W. Wolpin, E.M. O’Reilly , Ko Yoo-Joung, L.S. Blaskowsky, M.U. Rarick, C.M. Rocha-

Lima, P.S. Ritch, E. Chan, J.L. Spratlin, T. Macarulla, E. McWhirter, D. Pezet, M.

Lichinister, L Roman, A. Hartford, K. Morrison, L. Jackson, M. Vincent, L. Reyno, M.

Hidalgo. Global, Multicenter, open-labe, randomized phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastastic

pancreatic adenocarcinoma. Ann Oncol. 2013 Jul;;24(7):1792-801. doi: 10.1093.

62. J. Winter, L.H. Tang, D.S. Klimstra, M. Brennan, F. Rocha, R. Jia, Li-Xuan Qin, M.

D’Angelica, R.P. DeMatteo, Y. Fong, W.R. Jarnagin, E.M. O’Reilly , P.A. Allen. A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin

as biomarkers. PLoS One. 2012;;7(7):e40157. Epub 2012 Jul 6.

63. Ang, CS., Kelley, RK, Choti, MA, Cosgrove, DP, Chou, JF, Klimstra, D, Torbenson, MS,

Ferrell, L, Pawlik, TM, Fong, Y, O'Reilly, EM , Ma, J, McGuire, J, Vallarapu, GP, Griffin,

A, Stipa, F, Capanu, M, Dematteo, RP, Venook, AP, Abou-Alfa, GK. Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from

the fibrolamellar carcinoma consortium. Gastrointest Cancer Res. 2013 Jan;;6(1):3-9.

64. Lewis, G.H., Wang, H., Bellizzi, A.M., Klein, A.P., Askin, F.B., Schwartz, L.E., Schulick,

R.D., Wolfgang, C.L., Cameron, J.L., O’Reilly, E.M.

, Yu, K.H., Hruban, R.H. Prognosis of minimally invasive carcinoma arising in mucinous cystic neoplasms of the pancreas.

34

Am J Surg Pathol. 2013 Apr;;37(4):601-605.

65. Lee, JK, Capanu, M, O'Reilly, EM , Ma, J, Chou, JF, Shia, J, Katz, SS, Gansukh, B,

Reidy-Lagunes, D, Segal, NH, Yu, KH, Chung, KY, Saltz, LB, Abou-Alfa, GK. A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary

adenocarcinomas. Br J Cancer. 2013 Aug 20;;109(4):915-9. doi: 10.1038.

66. Faraj, W, Alameddine, R, Mukherji, D, Musallam, K, Haydar, A, Eloubiedi, M,

Shamseddine, A, Halal, A, Abou-Alfa, GK, O'Reilly, EM , Jamali, F, Khalife, M.

Postoperative outcomes following pancreaticoduodenectomy: how should age affect clinical practice? World J Surg Oncol. 2013 Jun 6;;11:131. doi: 10.1186/1477-7819-11-

131.

67. E.M. O’Reilly , A. Perelshteyn, W.R. Jarnagin, M. Schattner, H. Gerdes, M. Capanu, L.H.

Tang, J. LaValle, C. Winston, R.P. DeMatteo, M. D’Angelica, R.C. Kurtz, G.K. Abou-Alfa,

D.S. Klimstra, M.A. Lowery, M.F. Brennan, D.G. Coit, D.L. Reidy, T.P. Kingham, P.J.

Allen. A single-arm, non-randomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma. Ann Surg. 2014

Jul;;260(1):142-8. doi: 10.1097.

68. Abou-Alfa, GK, Capanu, M, O'Reilly, EM , Ma, J, Chou, JF, Gansukh, B, Shia, J, Kalin,

M, Katz, S, Abad, L, Reidy-Lagunes, DL, Kelsen, DP, Chen, HX, Saltz, LB. A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma. J

Hepatol. 2014 Feb;;60(2):319-24. doi: 10.1016.

69. Shamseddine, A.I., Mukherji, D., Melki, C., Elias, E., Eloubeidi, M., Dimassi, H. Khalife,

M., Abou-Alfa, G. O'Reilly, E . Faraj, W. Lymph node ratio is an independent prognostic factor after resection of periampullary malignancies: data from a tertiary referral center in the middle East. Am J Clin Oncol. 2014 Feb;;37(1):13-8. doi: 10.1097.

70. Liu, W., Shia, J., Gonen, M., Lowery, M.A., O’Reilly, E.M.

, Klimstra, D. DNA Mismatch

Repair Abnormalities in Acinar Cell Carcinoma of the Pancreas: Frequency and Clinical

Significance. Pancreas. 2014 Nov;;43(8):1264-70. doi: 10.1097.

71. Li, D, Pant, S, Ryan, DP, Laheru, D, Bahary, N, Dragovich,T, Hosein, PJ, Rolfe, L, Saif,

MW, LaValle, J, Yu, KH, Lowery, MA, Allen, A, O’Reilly, EM . A Phase II, Open-Label,

Multicenter Study to Evaluate the Antitumor Efficacy of CO-1.01 as Second-Line

Therapy for Gemcitabine-Refractory Patients with Stage IV Pancreatic Adenocarcinoma

and No Tumor hENT1 Expression. Pancreatology. 2014 10.1016/j.pan.07.003.

72. Yu, KH, Ricigliano, M, Hidalgo, M, Abou-Alfa, GK, Lowery, MA, Saltz, LB, Crotty, J,

Gary, K, Cooper, B, Lapidus, R, Sadowska, M, O’Reilly, EM . Pharmacogenomic

Modeling of Circulating Tumor and Invasive Cells for Prediction of Chemotherapy

Response and Resistance in Pancreatic Cancer. Clinical Cancer Research. 2014. Oct

15;;20(20):5281-9. doi: 10.1158/1078-0432.CCR-14-0531. Epub 2014 Aug 8.

73. Van Loon, K., Owzar, K., Jiang, C., Kindler, H.K., Mulcahy, M.F., Niedzwicki, D.,

O’Reilly, E.M.

, Fuchs, C., Innocent, F., Venook, A.P. 25-Hydroxyvitamin D Levels and

Survival in Advanced Pancreatic Cancer: Findings From CALGB 80303 (Alliance). J Nat

Cancer Inst. 2014 Aug 6;;106(8). pii: dju185. doi: 10.1093/jnci/dju185. Print 2014 Aug.

35

74. I. Sahin, A. Geyer, E.M. O’Reilly . Gemcitabine-related Pneumonitis An Infrequent

Event: Elucidation of Risk Factors and Management Implications. Clin Colorectal

Cancer. 2015 Aug 22. pii: S1533-0028(15)00110-3. doi: 10.1016/j.clcc.2015.08.003.

[Epub ahead of print].

75. J.M. Herman, D.T. Chang, K.A. Goodman, A.S. Dholakia, S.P. Raman, C. Iacobuzio-

Donahue, M.B. Griffith, T. Pawlik, J. Pai, E.M. O’Reilly , G. Fisher, A. Wild, L. Zheng, C.

Wolfgang, D.A. Laheru, L.A. Colombo, E. Sugar, A. Koong. Phase II Multi-Institutional

Trial Evaluating Gemcitabine and Stereotactic Body Radiation Therapy for Locally

Advanced Unresectable Pancreatic Adenocarcinoma. Cancer. 2014 Dec 23. doi:

10.1002/cncr.29161.

76. E.M. O’Reilly , A. Perelshteyn, W.R. Jarnagin, M. Schattner, H. Gerdes, M. Capanu, L.H.

Tang, J. LaValle, C. Winston, R.P. DeMatteo, M. D’Angelica, R.C. Kurtz, G.K. Abou-Alfa,

D.S. Klimstra, M.A. Lowery, M.F. Brennan, D.G. Coit, D.L. Reidy, T.P. Kingham, P.J.

Allen. A single-arm, non-randomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma. Ann Surg. 2014

Jul;;260(1):142-8. doi: 10.1097.

77. R. Yaeger, A. Cercek, E.M. O’Reilly , D. L-Reidy, N.E. Kemeny, T. Wolinsky, M. Capanu,

M. Gollub, N. Rosen, M.F. Berger, M.E. Lacouture, E. Vakiani, L.B. Saltz. Pilot trial of combined BRAF and EGFR inhibition in BRAF mutant metastatic colorectal cancer patients. Clin Cancer Res. 2015 Jan 14. pii: clincanres.2779.2014.

78. A.S. Epstein, E. Shuk, E.M. O’Reilly , K.A. Gary, A.E. Volandes. ‘We have to discuss it’:

Cancer patients’ advance care planning impressions following educational information about cardiopulmonary resuscitation. Pyschooncology. 2015. Feb 23. doi:

10.1002/pon.3786. [Epub ahead of print].

79. G.M. Nash, J.D. Smith, L. Tang, M.R. Weiser, L.K. Temple, E. O’Reilly , L.B. Saltz, J.G.

Guillem, P.B. Paty. Lymph node metastasis predicts disease recurrence in a single- center experience of 70 stages 1-2 appendix cancers: A retrospective review. Ann Surg

Oncol. 2015. Feb 7. [Epub ahead of print].

80. D. Li, M. Capanu, K.H. Yu. M.A. Lowery, D.P. Kelsen, E.M. O’Reilly . Treatment,

Outcomes and Clinical Trial Participation in Elderly Patients with Metastatic Pancreas

Adenocarcinoma. Clin Colorectal Cancer.

2015 May 22. pii: S1533-0028(15)00063-8. doi: 10.1016/j.clcc.2015.05.005. [Epub ahead of print].

81. S. Weber, D. Ribero, E.M. O’Reilly , N. Kokudo, M. Miyazaki, T. Pawlik. Intrahepatic

cholangiocarcinoma. HPB (Oxford). 2015 Aug;;17(8):669-80. doi: 10.1111/hpb.12441.

82. E. Sadot, A. Doussot, E.M. O’Reilly, M.A. Lowery, K.A. Goodman, R.K. Do, L.H. Tang,

M. Gonen, M.I. D’Angelica, R.P. DeMatteo, T.P. Kingham, W.R. Jarnagin, P.A. Allen.

FOLFIRINOX induction therapy for stage 3 pancreatic adenocarcinoma. Ann Surg

Oncol. 2015 Jun 12 [Epub ahead of print].

83. V.J. Picozzi, R.K. Ramanathan, M.A. Lowery, A.J. Ocean, E.P. Mitchell, B.H. O'Neil,

M.J. Guarino, P.R. Conkling, S.J. Cohen, N. Bahary, R.C. Frank, T. Dragovich, B.B.

Bridges, F.S. Braiteh, A.N. Starodub, F-C. Lee, T.E. Gribbin, D.A. Richards, M. Lee, R.L.

36

Korn, N. Pandit-Taskar, S.J. Goldsmith, C.M. Intenzo, A.Sheikh, T.C. Manzone, H.

84. Horne, R.M. Sharkey, W.A. Wegener, E.M. O’Reilly , D.M. Goldenberg, D.D. Von Hoff.

90 Υ-Clivatuzumab Tetraxetan With or Without Low-Dose Gemcitabine: A Phase IB Study in Patients with Metastatic Pancreatic Cancer after 2 or More Prior Therapies. Eur J

Cancer. 2015 Jul 14. pii: S0959-8049(15)00645-0. doi: 10.1016/j.ejca.2015.06.119

[Epub ahead of print].

85. E. Salo-Mullen, E.M. O’Reilly , D.P. Kelsen, A. Ashraf, M.A. Lowery, K. Yu, D. Reidy, A.

Epstein, A.G. Licoln, A. Salida, L.M. Jacobs, R. Murthy, L. Zhang, R. Kurtz, L.B. Saltz, K.

Offit, M. Robson, Z. Stadler. Identification of Germline Genetic Mutations in Pancreatic

Cancer Patients. Cancer. 2015 Oct 6. doi: 10.1002/cncr.29664.

86. L. Tang, D.Reidy, B. Untch , E.M. O’Reilly , Dhall Deepti, J. Lily, O. Basturk, P. Allen, D.

Klimstra. High Grade Progression of Well Differentiated Neuroendocrine Tumors: A

Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas. Clin Cancer

Research. (Accepted 09/15)

87. C.B. O’Neill, C. Swartz, E.M. O'Reilly , P. Bach, M.C. Henman, E. Elkin. Hospitalizations in Older Patients with Advanced Cancer: The Role of Chemotherapy. J Oncology

Practice. 2015 (Accepted 09/15).

In Review

88. F . Huguet, A. Wu, Z. Zhang, W. Shi, E.M. O’Reilly , C. Winston, D. Reidy, A. Ho, P.

Allen, K. Goodman. Chemotherapy and Intensity-Modulated Radiation Therapy for

Locally Advanced Pancreatic Cancer Achieves High Rate of R0 Resection and

Prolonged Survival . (In review, 2015).

89. S. Olsen, Y. Xu, K. Herzog, C. Salida, E. Defilip, P. Allen, E.M. O’Reilly , R. Kurtz.

Weight loss, diabetes, fatigue and depression preceding pancreatic cancer. Pancreas.

(In review, 07/15).

90. A.E. Epstein, E.M. O’Reilly , Paul K. Maciejewski, H. Prigerson. Discussions of life expectancy and changes in advanced cancer patients. J Clin Oncol. 2015 (Revision,

08/15).

2. Books, Book Chapters, Editorials, Reviews, Reports

91. E. O’Reilly, J. Crown. The medical treatment of advanced prostate cancer. Ir Med J.

1994 Sep-Oct;;87(5): 130-132.

92. E.M. O’Reilly , J.P. Crown. Anti-emetic therapy in oncology. Irish Medical Times, 1995,

36-37

93. L.E. Harrison, E. O’Reilly , B. Minsky, G. Schwartz, M.S. Karpeh. Mid and distal gastric cancers. Integrated Cancer Management, Ed. M. Torosian, 1997.

37

94. F.V. Coakley, E.M. O’Reilly, L.H. Schwartz, D.M. Panicek, R.A. Castillino. Non- hodgkin’s lymphoma as a cause of intrahepatic periportal low attenuation on computed tomography. J Comput Assist Tomogr. 1997 Sep-Oct;;21(5):726-8.

95. P.C. Enzinger, D.H. Ilson, L.B. Saltz, E.M. O’Reilly , D.P. Kelsen. Irinotecan and

Cisplatin in Upper Gastrointestinal Malignancies. Oncology (Williston Park). 1998

Aug;;12(8 Suppl 6):110-3.

96. E.M. O’Reilly , G.K. Schwartz, M. Karpeh, B. Minsky. Mid and distal gastric tumors. In:

M.H. Torosian, ed. Integrated cancer management: surgery, medical oncology and radiation therapy. [Book chapter]

97. P.W. Swanson, E.M. O’Reilly , W.K. Kelly. Chemotherapy in patients with androgen independent prostate cancer. In: F. Hamdy, J. Basler, D. Neal, W. Catalona, eds.

Management of Urologic Malignancies, 254-9, 2002. [Book chapter]

98. E.M. O’Reilly , D.P. Kelsen. Memorial Sloan-Kettering Cancer Center experience with intraperitoneal chemotherapy for gastric cancer. In: M. Markman, ed. Regional

Chemotherapy in the Management of Malignant Disease. Totowa NJ: Humana Press;;

249-261, 2000. [Book chapter]

99. E.M. O’Reilly . Vaccine Therapy for Pancreatic Cancer. In: MD Anderson Solid Tumor

Oncology, Pancreatic Cancer. Evans, DB, Pisters, P.W.T., Abbruzzese, J., eds.

Springer-Verlag, 347-57, 2002. [Book chapter].

100.

101.

102.

E.M. O’Reilly

E.M. O’Reilly

E.M. O’Reilly

. Colorectal Cancer: Index & Reviews, Vol 1, No. 2, 2000.



103.

104.

E.M. O’Reilly . Colorectal Cancer: Index & Reviews, Vol 3, No. 3, 2003.

E.M. O’Reilly , D.P. Kelsen. Adjuvant therapy of Pancreas cancer. Review

Commentary. Oncology. 11, 2001.

105. E.M. O’Reilly.

Gemcitabine and Irinotecan in advanced gastrointestinal malignancies. Cancer Invest. 2000, vol 18 (Suppl. 1).

106. E.M. O’Reilly , D.H. Ilson. Cisplatin and Irinotecan in upper gastrointestinal malignancies. Oncology (Williston Park). 2001 Mar;;15(3 Suppl 5):42-5.

107. E. M. O’Reilly . Biliary Tree Cancers. Review Commentary. Oncology, 2002.

108. J. Konner, E.M. O’Reilly . Epidemiology, Genetics and Screening for Pancreatic

Cancer. Oncology (Williston Park). 2002 Dec;;16(12):1615-22, 1631-2;; discussion 1632-

3, 1637-8.

109. E.M. O’Reilly , J. Kelvin. 100 Questions & Answers about Pancreatic Cancer.

Jones & Bartlett, 2002 [Book].

38

110. Weber, S;; O'Reilly, EM ;; Abou-Alfa, GK;; Blumgart, L: Liver and Bile Duct Cancer.

In: Abeloff, M;; Armitage, J;; Lichter, A;; and Niederhuber, J, eds. Clinical Oncology , 3 rd ed. Philadelphia, PA. Churchill Livingstone, 2004.

111. E. M. O’Reilly , J. Konner. Chapter 34, Clinical Trials and Methodology.

Pancreatic Cancer, 1 st Edition. Von Hoff, et al. Jones & Bartlett, 2004.

112.

113.

E.M. O’Reilly

E.M. O’Reilly

. Colorectal Cancer. Index & Reviews, Vol. 4, No. 3, 2003.

. Colorectal Cancer: Index & Reviews, Vol. 5, No. 1, 2004.

114. G. Leonard, E.M. O’Reilly , C. Allegra. Biliary Tree Cancer. Bethesda Handbook of Clinical Oncology, 2005. Abraham, et al. Lippincott Williams & Wilkins.

115. G.D. Leonard, E.M. O’Reilly . Post-operative chemotherapy improves disease- free, but not overall survival in people with oesophageal squamous cell carcinoma.

Cancer Treat Rev, 2004: Aug;;30(5):473-7.

116. G.D. Leonard, E.M. O’Reilly. Pancreatic Cancer. Adjuvant therapy. Secrets in medical Oncology, 2004. [Book Chapter].

117. E. M. O’Reilly.

Colorectal Cancer: Index & Reviews, Vol 6, No. 2, 2005.

118. G.D. Leonard, E.M. O’Reilly . Biliary tract cancers: Current concepts and controversies. Expert Opin Pharmacother. 2005 Feb;;6(2):211-23.

119. Deming, D.A., Stella, A.L., Holen, K.D. Ku, G., O'Reilly, E.M

. A dramatic response to long-acting octreotide in metastatic hepatocellular carcinoma. Clin Adv

120.

Hematol Oncol. 2005 Jun;;3(6):468-72;; discussion 472-4.

E.M. O’Reilly . Colorectal Cancer: Index & Reviews, Vol 6, No.4, 2006

121.

2007.

A. Duffy, E.M. O’Reilly . Colorectal Cancer: Index & Reviews, Vol, 7, No. 1,

122. E.M. O’Reilly , G.K. Abou-Alfa. Cytotoxic Chemotherapy for Advanced Pancreas

Adenocarcinoma (Review). Semin Oncol. 2007 Aug;;34(4):347-53.

123. Hochster, H.S., O'Reilly, E.M.

, Ajani, J.A., Venook, A.P. Section III: Treatment of Advanced Gastrointestinal Cancers. Gastrointest Cancer Res. 2007 Nov;;1(6

Suppl):S8-S12.

124. Goldberg, R.M., Marshall, J.L., Ajani, J.A., Philip, P.A. O'Reilly, E.M.

, Venook,

A.P. Section IV: Significance of Recent Study Results and Future Research Directions

in Gastrointestinal Oncology. Gastrointest Cancer Res. 2007 Nov;;1(6 Suppl):S13-6

125. G.K. Abou-Alfa, F.D. Huitzil-Melendez, E.M. O’Reilly , L.B. Saltz. Current

Management of Advanced Hepatocellular Cancer. Gastrointest Cancer Res. 2008

Mar;;2(2):64-70.

39

126. S. Weber, W. Jarnagin, E.M. O’Reilly , A. Duffy, G.K. Abou-Alfa, L. Blumgart.

Chapter 84. Liver and Bile Duct Cancer. Abeloff’s Clinical Oncology, 4 th Edition.

Abeloff, et al. Churchill Livingstone Elsevier, 2008.

127. G.K. Abou-Alfa, F.D. Huitzil-Melendez, E.M. O'Reilly , L.B. Saltz. Current management of advanced hepatocellular cancer. Gastrointest Cancer Res. 2008

Mar;;2(2):64-70.

128. E.M. O’Reilly , G.K. Abou-Alfa. Comparison of gemcitabine plus platinum analog with gemcitabine alone in advanced pancreas cancer. Nat Clin Pract Oncol. 2008

Jun;;5(6):312-3. Epub 2008 Apr 29.

129.

2 nd

E.M. O’Reilly, J. Kelvin. 100 Questions and Answers about Pancreas Cancer.

Edition, 2009. Jones & Bartlett.

130. A. Duffy, J. Shia, D. Klimstra, L. Temple, E.M. O'Reilly . Collision tumor of the large bowel in the context of advanced pregnancy and ulcerative colitis. Clin Colorectal

Cancer. 2008 Nov;;7(6):402-5.

131. A. Duffy, J. Shia, F.D. Huitzil-Melendez, Y. Fong, E.M. O'Reilly . Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in

unresectable metastatic colorectal cancer. Clin Colorectal Cancer. 2008 Mar;;7(2):140-3.

132. A. Duffy, E.M. O'Reilly . Areas of Confusion in Oncology: Localized Pancreas

Adenocarcinoma. Oncology (Williston Park). 2008 Oct;;22(11):1283-91;; discussion

1294, 1296-8.

133. R.J. Motzer, H.L. Kindler, E.M. O’Reilly . Expert Insights. New Frontiers in

Targeted Therapy for Advanced Pancreatic Cancer. Part 2: Optimizing outcomes for

individualizing therapy. Feb, 2009.

134. F.D. Huitzil-Melendez, E.M. O’Reilly , A. Duffy, G.K. Abou-Alfa. Indications for neoadjuvant, adjuvant and palliative chemotherapy in the treatment of biliary tract cancers. Surg Oncol Clin N Am. 2009 Apr;;18(2):361-79.

135. E.M. O’Reilly . Pancreatic Adenocarcinoma: New Strategies for Success.

Gastrointest Cancer Res. 2009 Mar;;3(2 Suppl):S11-5.

136. S. Nagula, W.R. Jarnagin, E.M. O’Reilly , M. Schattner. Capsule-induced small bowel obstruction during video capsule endoscopy in a patient with carcinomatosis. Dig

Dis Sci. 2010 Jun;;55(6):1778-80. Epub 2009 Aug 6.

137. Yang Lu, E.M. O’Reilly , J. Carrasquillo. Lack of Splenic Uptake of 111In- pentetreotide Due to Splenic Embolization. Clin Nucl Med. 2009 Dec;;34(12):960-1.

138. J.W. Feilchenfeldt, E.M. O’Reilly , C. Albany, G.K. Abou-Alfa. Targeted therapies for hepatocellular carcinoma. Hepatocellular carcinoma. McMasters, KM, Vauthey, JN,

Editors. (Book chapter).

139. E.M. O’Reilly , Angela McIntosh. Clinical trial to clinical practice: A review of promising clinical data in combination therapy for advanced pancreatic cancer.

40

Community Oncology. 2009.

140. E.M. O’Reilly , M. Lutz, P. Neuhaus. Accomplishments in 2008 in the management of localized pancreatic cancer. Gastrointest Cancer Res. 2009 Sep;;3(5

Supplement 2):S37-42.

141. R. Said, E.M. O’Reilly , L. Blumgart, J. Shi, G.K. Abou-Alfa. Pancreatic islet cell carcinoma presenting with concurrent cushing’s and Zollinger-Ellison syndromes: Case

series and literature reivew. Eur J Gastroenterol Hepatol. 2010 Feb;;22(2):246-52.

142. T. Saliba, S. Dorkhom, E.M. O’Reilly , E. Ludwig, B. Gansukh, G.K. Abou-Alfa.

Hepatocellular carcinoma in two patients with cardiac cirrhosis. Eur J Gastroenterol

Hepatol. 2010 Jul;;22(7): 889-91.

143. M. Lowery, E.M. O’Reilly . Targeted therapies for pancreatic adenocarcinoma.

Minerva Chir. 2009 Oct;;64(5):501-19.

144. D. Power, J. Shia, P.J. Allen, W.R. Jarnagin, E.M. O’Reilly.

Synchronous epithelial and neuroendocrine cancers of the pancreas: Case reports of a rare

occurrence. Clin Colorectal Cancer. 2011 Jun:10(2):146-150. Epub 2011 Apr 27.

145. M. Lowery, E.M. O’Reilly . DxRx Pancreas Cancer. 1 st edition. Jones & Bartlett.

2010.

146. E.M. O’Reilly . Adjuvant Therapy for Pancreas Cancer in 2010: Therapy

Refinement. Editorial. JAMA. 2010 Sept;;304(10):1124-25.

147. M. Lowery, D. Klimstra, C. Hedvat, W.R. Jarnagin, D. Chi, E.M. O’Reilly . A case of synchronous mucinous ovarian and pancreatic tumors: Use of kras mutation molecular phenotyping to demonstrate independent primary origin. Gastrointest Cancer

Res. 2012 Mar;;5(2):67-70.

148. M. Lowery, M.A. Shah, E. Smyth, A. Epstein, A. Segal, O. Rosengarten, R.

Isacson, L. Drukker, A. Keinan, M. Rachkiman, P. Reissman, A. Gabizon, D. Kelsen,

E.M. O’Reilly . A 67 year-old woman with BRCA-1 mutation associated with Pancreatic

Adenocarcinoma. J Gastrointest Cancer. 2011 Sep;;42(3):160-4.

149. M.A. Lowery, E.M. O’Reilly . New Approaches to the Treatment of Pancreas

Adenocarcinoma: From Tumor-Directed Therapy to Immunotherapy. Biodrugs. 2011:

Aug 1;; 25(4) 1-10.

150. Lowery, M.A., O’Reilly, E.M

. Pancreatic cancer: the role of molecular markers in diagnosis and management. Clin Adv Hematol Oncol. 2011 Dec;;9(12):900-8.

151. Abou-Alfa, GK ;; Ang, C;; O’Reilly, EM : Novel Therapeutics For Liver Tumors in:

Fong, Y, Abou-Alfa, GK, Dang, G, Dong, J, Dupuy, D, Poon, R, ed: “Hepatobiliary

Cancer: Diagnosis and Treatment.” (in press).

152. A.E. Epstein, E.M. O’Reilly , M. Lowery, A. Shamseddine, J. Shia, S. Temraz, A.

Al-Olayan. M. Naghy, D. Kelsen, M.A. Shah, G.K. Abou-Alfa. A woman with remotely treated pancreas cancer and new abdominal pain: A discussion of evaluation and

41

management. J Gastrointest Cancer. 2010, Dec 07. DOI 10.1007/s12029-010-9234-0.

153. C. Ang, E.M. O’Reilly , G.K. Abou-Alfa, A. Shamseddine, H. Skouri, A. Tawil,

M.E. Eloubeidi, M. Lowery, M. Kharfan-Dabaja, T. Kaprealian, S. Temraz, H. Sibai, H.

Faran, M.A. Shah. Management of metastatic adenocarcinoma of unknown primary origin in a Ph+ ALL survivor. J Gastrointest Cancer. 2011 Sep;;42(3):165-70.

154. M. Lowery, E.M. O’Reilly . Genomics and Pharmacogenomics of Pancreas

Adenocarcinoma. The Pharmacogenomics J. 2012 Feb;;12(1):1-9. doi:

10.1038/tpj.2011.52. Epub 2011 Dec 20.

155. Postow, M., M.A. Shah, M. Lowery, A. Shemseddine, A. El-Kutubi, A. Olayan, M.

Naghy, C. Ang, S. Tamraz, A.R. Jazieh, E.M. O’Reilly , D.P. Kelsen, G.K. Abou-Alfa. A

Man with Klinefelter’s Syndrome and New Abdominal Distension: A Discussion of

Evaluation and Management. J Gastrointest Cancer. 2012 Jun;;43(2):314-8.

156. E.M. O’Reilly . Adjuvant Therapy for Pancreas Adenocarcinoma: Where Are We

Going? Expert Rev Anticancer Ther. 2011 Feb;;11(2): 173-177.

157. C.Y. Hu, Y. Zhong, L. Giulino, S. Ho, A. Loizides, D. Manwani, E.M. O’Reilly ,

A.W. Seymour. A rare case of childhood pancreatic ductal adenocarcinoma diagnosed by endoscopic ultrasound-guided fine needle aspiration. Pediatric Blood and Cancer.

(In review 06/11).

158. C. Ang, E.M. O’Reilly , G.K. Abou-Alfa. MicroRNA, Hypoxic Stress and

Hepatocellular Carcinoma: Future Directions. J Gastroenterol Hepatol. 2011 Nov;;

26(11): 1586-1588.

159. E. Pentsova,A. Liu, M. Rosenbaum, E.M. O’Reilly , Xi Chen, A. Hormigo.

Gemcitabine Induced Myositis in Patients with Pancreatic Cancer: Two Case Reports

and Literature Review. J NeuroOncol. 2012 Jan;; (106)1:15-21.

160. A.E. Epstein, E.M. O’Reilly . Invited editorial. Targeting Thrombosis in Exocrine

Pancreas Cancer: A Continued Need for Improved Therapies. Expert Rev Anticancer

Ther. 2011 Dec;;11(12):1783-5.

161. C. Ang, A. Abu-Alfa, K.Abdullah, M. Lowery, H. Sibai, H. El Farran, S. Tamraz, A.

Al Olayan, A. Shamseddine, M. Naghy, W. Faraj, E.M. O’Reilly , G.K. Abou-Alfa.

Hepatocellular carcinoma following renal transplantation. Gastrointest Cancer Res. 2011

Sep;;4(5-6):180-3.

162. Karamurzin, Y, Z. Zeng, Z.K. Stadler, L. Zhang, I. Quansafi, H.A. Al-Ahmadie, C.

Sempoux, L.B. Saltz, R.A. Soslow, E.M. O’Reilly , P.B. Paty, D.G. Coit, J. Shia, D.S.

163. E.M. O’Reilly . Adjuvant Therapy for Pancreas Adenocarcinoma. Current

Therapy and Future Directions. J Surg Oncol. 2012 Aug 6. doi: 10.1002/jso.23230.

Klimstra. Unusual DNA mismatch repair deficient tumors in Lynch syndrome: a report of new cases and review of the literature. Hum Pathol. 2012 Oct;;43(10):1677-87.

42

164. E.M. O’Reilly , M.A. Lowery. Post-resection surveillance for pancreas cancer –

Performance status, imaging and serum markers. Cancer J. 2012 Nov;;18(6):609-13.

165. Epstein, A.S., Abou-Alfa, G.K., Shamseddine, A., Al-Olayan, A., Ang, C, Naghy,

M, Lowery, MA, O’Reilly, E.M

. Communication and palliative care in a 64-year old man

with pancreatic adenocarcinoma. Gastrointest Cancer Res. 2012 Jul;;5(4):130-4.

166. Ang, C. O’Reilly, E.M.

, Abou-Alfa, G.K. Targeted agents and systemic therapy in hepatocellular carcinoma. Recent Results Cancer Res. 2013;;190:225-46.

167. Snyder, A, Allen, P, Shamseddine, A, Haydar A, Eloubeidi, M, Faraj W, Khalife

M, Temraz S., El-Olayan, A, Kelsen, DP, El-Merhi, F, Naghy M, Saltz, LB, Abou-Alfa,

GK, O’Reilly, E.M.

Neoadjuvant therapy in clinical stage II pancreatic adenocarcinoma.

Gastrointest Cancer Res. 2012 Sep;;5(5):169-73.

168. Muhkherji, D, Faraj W, Khalife M, Shaseddine A, El Majzoub N, Zaatari, G, Shah

M, Abou-Alfa, GK, O’Reilly, EM.

A 71-year old man with a large cystic pancreatic mass.

Gastrointest Cancer Res. 2012 Jan;;5(1):29-31.

169. Owen, D, O' Reilly, EM , Ang, C, Ma, J, Do, RK, Abou-Alfa, GK. Optimal chemotherapy dosing in a bilateral lower extremities amputee with metastatic pancreatic

adenocarcinoma. Gastrointest Cancer Res. 2013 May;;6(3):93-4.

170. Mankal, P, O’Reilly, EM . Sunitinib Malate for Pancreas Malignancies – where does it Fit? Expert Opin Pharmacother. 2013 Apr;;14(6):783-92. doi:

10.1517/14656566.2013.776540.

171. O’Reilly, EM . The evolving panorama of treatment options for metastatic pancreas cancer. Editorial. J Clin Oncol. 2013. 10.1200/JCO.2013.48.7660.

172. Dbouk, H, Mentha, S, Mukherji, D, Lee, J, Haydar, A, Shamseddine, A, O'Reilly,

EM , Saltz, L, Abou-Alfa, GK. A 39-year-old female patient with metastatic rectal cancer

develops thrombocytopenia. Gastrointest Cancer Res. 2014 Mar;;7(2):55-8.

173. Won, E, Yu, KH, Shamseddine, A, Saltz, L, Mukherjee, D, Haydar, A, El-Olayan, A,

Temraz, S, Naghy, M, Makanjoula, D, O'Reilly, EM , Abou-Alfa, GK. Management of a patient diagnosed with pancreatic cancer and myelodysplastic syndrome. Gastrointest

Cancer Res. 2013 Mar;;6(2):56-60.

174. Dbouk, H, Ajouz, H, Shamseddine, A, Mukherji, D, O'Reilly, EM , Haydar, A, Kelsen,

D, Naghy, M, Eloubeidi, M, Geara, F, Saltz, L, Abou-Alfa, GK. Modified GTX as Second-

Line Chemotherapy in Advanced Pancreatic Cancer. Gastrointest Cancer Res. 2013

Jul;;6(4):115-7.

175. Aboul Hosn, M, Abdel-Hafiez, N, Abdel-Wahab, R, Al-Ahmadie, A, Antar, A, Dbouk,

H, El Farran, H, El-Sawy Mohamed, M, Rida, K, Mukherji, D, O'Reilly, EM , Garcia-

Aguilar, J, Abou-Alfa, GK. A giant rectal villous adenoma with a malicious intent.

Gastrointest Cancer Res. 2013 Sep;;6(5-6):144-9.

176. GK. Abou-Alfa, W. Jarnagin, M. Lowery, M. D’Angelica, K. Brown, E. Ludwig, A.

Covey, N. Kemeny, KA. Goodman, J. Shia, and EM. O’Reilly . Liver and Bile Duct

43

Cancer. Chapter 80. Abeloff's Clinical Oncology, 5th Edition. Abeloff, et al. Churchill

Livingstone Elsevier, 2013.

177. E.M. O’Reilly.

Adjuvant Therapy for Pancreas Adenocarcinoma. J Surg Oncol.

2013;;107(7):78-85.

178. Abou-Alfa, GK;; O’Reilly, EM . 100 Questions and Answers About Gallbaldder and biliary cancers, 1 st ed. Sudbury, MA: Jones and Bartlett (2013).

179. Shoushtari, A.N., Covey, A.M., Zaatari, G., Shamseddine, A., Epstein, A.S.,

Haydar, A., Naghy, M., Mukherji, D., Kelsen, D.P., Abou-Alfa, G.K., O'Reilly, E.M

. A woman with metastatic pancreatic neuroendocrine tumor. Gastrointest Cancer Res.

2014 Jan;;7(1):27-32.

180. Lowery, MA., O’Reilly, EM . Treatment of metastatic pancreatic adenocarcinoma: new options and promising strategies. Oncology. 2014 Jan;;28(1):76,

78.

181. T. Seufferlein, J.L. Van Laethem, E. Van Cutsem, J. D. Berlin, M. Büchler, A.

Cervantes, K. Haustermans, M. Hidalgo, E.M. O’Reilly , C. Verslype, W. Schmiegel, P.

Rougier. The management of locally advanced pancreas cancer: European Society of

Digestive Oncology (ESDO) expert discussion and recommendations from the 14 th

ESMO/World Congress of Gastrointestinal Oncology, Barcelona. Ann Oncol. 2014 (25)

Suppl 2. doi:10.1093/annonc/mdu163.

182. D. Li, E.M. O’Reilly . Adjuvant and Neoadjuvant Systemic Therapy for Pancreas

Adenocarcinoma. Semin Oncol. 2015 Feb;;42(1):134-143.

183. M. Lowery, E.M. O’Reilly . Novel Therapeutics for Pancreas Adenocarcinoma.

Hematol Oncol Clin North Am.

2015 Aug;;29(4):777-787. doi:

10.1016/j.hoc.2015.04.006.

184. A. Yang, E.M. O’Reilly . Novel directions in neoadjuvant therapy for pancreas adenocarcinoma. Expert Rev Gastroenterol Hepatol. 2015 Feb 16:1-17.

185. Samdani, R.T., Hechtman, J.F., O’Reilly, E., DeMatteo, R., Sigel, C.S. EBV- associated lymphoepithelioma-like carcinoma of the pancreas: Case report with targeted sequencing analysis. Pancreatology. 2015 Apr 9. pii: S1424-3903(15)00072-1. doi:

10.1016/j.pan.2015.03.016. [Epub ahead of print].

186. Li, D., O’Reilly, E.M.

Adjuvant and Neoadjuvant Therapy for Pancreatic

Adenocarcinoma. Surgical Oncology Clinics of North America. Pancreatic Neoplasms.

Elsevier. 2015. [Book Chapter].

187. Snyder, A., Kemeny, N., Shemseddine, A., Al-Olayan, A., El-Merhi, F., Kelsen,

D., Jamali, F., Sidani, M., Mukherji, D., El-Naghy, M., O’Reilly, E.M

., Saltz, L.B., Abou-

Alfa, G.K. Liver directed conversion therapy in metastatic colon cancer. J Gastrointest

Oncol. 2015 Jun, 6(3);;322-8.

188. Knudsen, E.K.

O’Reilly, E.M., Brody, J. Witkiewicz, A. Genetic Diversity of

Pancreas Adenocarcinoma and Emerging Opportunities in Precision Medicine.

44

Gastroenterology. 2015 Sep 15. pii: S0016-5085(15)01314-1. doi:

10.1053/j.gastro.2015.08.056. [Epub ahead of print].

189. M.A. Lowery, E.M. O’Reilly . PALB2 mutations confer susceptibility to familial pancreatic cancer but may suggest novel therapeutic approaches for cancer.

Contemporary Oncology. 2015 (In press).

190. Sahin, I.H., Iacobuzio-Donahue, C., O’Reilly, E.M

. Molecular Signature of

Pancreatic Adenocarcinoma: An Insight from Genotype to Phenotype and Challenges for Targeted Therapy. Expert Opin Ther Targets. 2015 Oct 6:1-19.

45

Selected Web and Other Activities

1. University of Florida, Peerview Press. Improving Survival in Pancreas Cancer:

Strategies for EGFR inhibition. Course Co. Director, E.M. O’Reilly , 2006.

2. University of New Mexico, Peerview Press. Case Studies on Management of Pancreatic

Cancer: Current Challenges and Latest Evidence. Course Director: E.M. O’Reilly .

2007. http://www.peerviewpress.com/activity.do?id=897&topic=All_Topics&autoplay=true&seq

=1

3. Improving Outcomes in Pancreatic Cancer: Existing Options and Novel Approaches.

Course Director: E.M. O’Reilly . 2009.

http://aapeadvancesinpc.stream57.com/?mptts=20090820095835

4. Treatment Options for Pancreas Cancer (MedPage, AAPE). Boston, 2010.

E.M. O’Reilly .

5. Purdue University Peerview Press. Clinical Horizons in Advanced Pancreatic Cancer: A

Case-based Roundtable Discussion of Established and Emerging Therapies. Course

Director, E.M. O’Reilly , 2010.

6. E.M. O’Reilly . Course Director. Educational Concepts. The Quality Care Continuum in

Advanced Pancreatic Cancer. 2010.

7. E.M. O’Reilly . Gastrointestinal Cancer Update. Bridging the Gap between Research and Patient Care. Faculty. 2010. Vol 1, issue 2.

8. MSKCC Pancreas CME Symposium: Pancreatic Neoplasms: Controversies and

Challenges. New York, NY 10/10. E.M. O’Reilly , Co-Director & Faculty.

9. E.M. O’Reilly , A.E. Epstein. Recent Findings in Pancreatic Cancer: Illuminating

Emerging Treatment Strategies. Medscape, 2010. http://cme.medscape.com/viewarticle/728727

10. E.M. O’Reilly , C. Crane. American Society of Clinical Oncology (ASCO) University

Tumor Boards: Pancreatic Cancer. ASCO, 2011. http://university.asco.org/tumorboards

11. E.M. O’Reilly . Treatment Advances in Resected and Locally Advanced Pancreatic

Adenocarcinoma. European School of Oncology, 2011. http://www.e-eso.net

12. A. Benson, W.R. Jarnagin, S. Kopetz, E.M. O’Reilly . Update on Antiangiogenic Therapy

for Metastatic Colorectal Cancer and Advanced Hepatocellular Carcinoma. 2011.

13. E.M. O’Reilly . Diagnosis and Management of Pancreas Cancer. 2011. http://cancerclinician.com/videolibrary/page/2/

46

Date:

Signature:

14. E.M. O’Reilly , G. Varadachary. Update on the Treatment of Pancreatic Cancer.

CANCER CARE . Feb, 2012. Nov, 2012. May, 2013.

15. E.M. O’Reilly. ASCO update on Pancreas Cancer. CANCER CARE . June 2013.

16. E.M. O’Reilly . ASCO update on Pancreas Cancer. CANCER CARE . June 2014.

17. E.M. O’Reilly , M. Tempero. P. Philip. Community-Expert Conversations in Pancreatic

Adenocarcinoma: New Therapies and Novel Concepts for Daily Practice. PeerView

Press. http://www.peerviewpress.com/d37 . August 2014.

18. E.M. O’Reilly, G. Varadachary. Pancreas Cancer. CANCER CARE . Jan 2015.

19. E.M. O’Reilly. Treatment updates in Pancreas Cancer. OncLive. Jan 2015.

20. E.M. O’Reilly . Treatment update on Pancreas Cancer. CANCER CARE.

June 2015.

21. E.M. O’Reilly . ASCO update on Pancreas Cancer. CANCER CARE . June 2015.

22. E.M. O’Reilly , J. Bendell. Gastrointestinal (Colorectal and Noncolorectal) Cancer:

Conference Highlights from the 2015 ASCO Annual Meeting. August 2015.

http://www.ecgcme.com/online-education/gastrointestinal-colorectal-and-noncolorectal- cancer-conference-highlights-2015

47

Memorial Sloan Kettering Cancer Center Weill Cornell Medical

Related documents

Products

Support

Memorial Sloan Kettering Cancer Center Weill Cornell Medical

Related documents

Add this document to collection(s)

Add this document to saved

Suggest us how to improve StudyLib